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INTRODUCTION 
SOLID ORAL DOSAGE FORMS 
 Historically, the most convenient and commonly employed route of drug delivery has 
been by oral ingestion.1 Oral drug delivery has been known for decades as the most widely 
utilized route of administration among all the routes that have been explored for the systemic 
delivery of drugs via various pharmaceutical products of different dosage forms. It is 
considered as the most natural, uncomplicated, convenient and safe route.2 
 Tablets are solid dosage forms containing medicinal substances with or without suitable 
diluents. They are the most widely preferred form of medication both by pharmaceutical 
manufacturer as well as physicians and patients. They offer safe and convenient ways of active 
pharmaceutical ingredients (API) administration with excellent physicochemical stability in 
comparison to some other dosage forms, and also provide means of accurate dosing. They can 
be mass produced with robust quality controls and offer different branding possibilities by 
means of colored film coating, different shapes, sizes or logos.3 
 Capsules are solid dosage forms in which drug is enclosed within either a hard or soft 
soluble shell. The shells are generally made up of gelatin. The capsules may be regarded as the 
container drug delivery system for powder and non powder filling such as tablets, capsules and 
pellets.4 
Advantages of Solid Oral Dosage Forms 5 
• They are the most stable dosage form with respect to their physical, chemical and    
microbiological attributes. 
• Provide an accurate, stable dose with greatest precision and least content variability, 
easy to use, handle and to be carried by the patient. 
• They are attractive and elegant in appearance. 
• The manufacturing cost of tablets is low as compared to other dosage form and their 
manufacturing speed is also quite high. 
• The packaging and shipping of tablets is comparatively easy and cheap. 
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• The unpleasant taste and odor of medicament(s) can be easily masked 
• The incompatibilities of medicament(s) and their deterioration due to environmental 
factors are less. 
• They are more suitable for large scale production. 
• Their identification is probably the easiest because of variety of shapes and colors. 
• They are formulated with certain special release profile products such as enteric or 
delayed   release products. 
• They are the lightest and most compact dosage form. 
Disadvantages of Solid Dosage Forms5 
• Drugs that are amorphous in nature or have low density character are difficult to be 
compressed into tablet. 
•  Hygroscopic drugs are not suitable candidate for compressed tablets. 
• Drugs having poor wetting properties, slow dissolution profile and high optimal gastro     
intestinal absorption are difficult or impossible to formulate as a tablet. 
• Drugs having bitter taste and objectionable odor require special treatment like coating   
or encapsulation which may increase their production cost. 
• Some drugs which preferably get absorbed from the upper part of GIT may cause 
bioavailability problem in tablet dosage form. 
• Capsules cannot be used for extremely soluble materials such as potassium chloride, 
potassium bromide. 
• Capsules cannot be used for highly efflorescent or deliquescent fill materials. 
Method of manufacturing of solid dosage forms 
Tablets 3 
 Different types of tablet formulations are available, which could be broadly classified 
based on route of administration such as tablets for oral, sublingual delivery, buccal delivery, 
rectal delivery or vaginal delivery and formulation characteristics such as immediate release 
tablets, effervescent tablets, melt-in-mouth or fast dissolving tablets, delayed release or 
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extended release tablets.  In all the cases, the general manufacturing process, machinery used 
for preparation of tablets and materials used are similar. 
TYPES OF TABLET MANUFACTURING 3 
 The tablet manufacturing process can be broadly classified as 
• Direct compression 
• Granulation 
 
Direct compression 3 
 Direct compression is used when a group of ingredients can be blended, placed onto a 
tablet press and made into a perfect tablet without any of the ingredients having to be changed. 
Powders that can be blended and compressed are commonly referred to as directly 
compressible or as direct-blend formulations. The inherent physical properties of the 
individual filler materials are highly critical, and minor variations can alter flow and 
compression characteristics, so as to make them unsuitable for direct compression. 
 The most widely used direct compression fillers are cellulose derivatives (e.g. 
microcrystalline cellulose), saccharides (e.g. lactose and mannitol), mineral salts                  
(e.g. Dicalcium phosphate, calcium carbonate) and partially pregelatinized starch. 
Granulation 3 
 Granulation is an agglomeration process to improve the flow, density and compressibility 
of particulate material by size enlargement and densification. Granulation can be achieved by 
the use of binder solution (wet granulation) or dry binder (dry granulation). 
Wet granulation 3 
 When powders are very fine, fluffy, will not stay blended, or will not compress, then they 
must be granulated. Wet massing is the process of adding a solution to a blended powder and 
mixing for a predetermined period of time at a given mechanical speed. Once the process is 
complete, the wet mass is milled, spread on trays dried in a tray dryer. The formed granules are 
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milled and compressed. Examples of wet granulation methods include fluid bed, high shear, 
pelletization techniques, such as extrusion spheronization and spray drying. 
Dry granulation 3 
Dry granulation (roll compaction or slugging) involves the compaction of powders at 
high pressures into large, often poorly formed tablets or compacts. These compacts are then 
milled and screened to form a granulation of the desired particle size. The advantage of dry 
granulation is the elimination of heat and moisture in the processing. Dry granulations can be 
produced by extruding powders between hydraulically-operated rollers to produce thin cakes 
that are subsequently screened or milled to give the desired granule size. 
 
Table 1.1: Granulation Methods3 
Method Advantage Limitations 
Direct 
compression 
Simple, economical process, 
No heat or moisture, so good 
for unstable compounds. 
Not suitable for all API, generally limited 
to lower dose compounds, Segregation 
potential, expensive excipients 
Wet Granulation Robust process, reduce 
elasticity problems, wettablity, 
reduced segregation potential. 
Expensive, Time and energy consuming, 
Specialized equipment, Stability issues. 
Wet Granulation 
(Non Aqueous) 
Vacuum drying technique, 
Suitable for moisture sensitive 
API 
Expensive equipment, solvent recovery 
issues, needs organic facility, health and 
environmental issues. 
Dry Granulation Eliminates exposure to 
moisture and drying 
Dusty procedure, slow process, not 
applicable for all API 
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MANUFACTURE OF CAPSULES 
  Immediate-release or Altered release hard gelatin capsules require the following 
common operations. 
• Rectification i.e. body
• Separation of caps from bodies
• Dosing of Fill Material
• Replacement of caps and ejection of filled capsules
• Finishing includes de
Hard gelatin capsule dimensions and filling capacities
Introduction
 
5, 6 
-end downward orientation 
 
 (Powder or Non powder filling) 
 
-dusting and polishing. 
 
7
 
 1 
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Extended Release Formulation 8 
 The formulated solid oral dosage form when administered reaches the absorption site and 
ends with its elimination in the original or modified form, through the normal channel of 
excretion. Hence in order to prolong the residence of drug in the body, dosing interval can be 
extended either by  
 Altering the release rate of a dosage form to retard the rate of absorption (ka)                       
 Slowing down of biotransformation rate 
 Manipulating the drug molecule to reduce the rate of elimination(kel) 
  Retarding the absorption rate in designing drug product provides well controlled drug 
concentration in blood stream. It is also necessary to take into account the physiological 
constraint of a finite residence time at the absorption site as in case of GI transit time. 
Factors involved in slowing the absorption rate 9 
• Route of administration  
• Vasoconstriction  
• Dissolution rate  
• Decreased solubility  
• Particle size and surface area  
• Slowing the disintegration and dissolution rate  
• Polymerization  
• Viscosity and nature of vehicle  
• Esterification  
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Fig 1.1: Blood profiles 
• An ideal dosage regimen in the drug therapy of any disease immediately attains the desired 
therapeutic concentration of drug in plasma or at the site of action and maintains it as a 
constant for the entire duration of treatment.9 
•  Administration of drug by conventional drug delivery systems does not maintain blood 
levels of drug within the therapeutic range for extended periods of time and associated with 
saw-tooth kinetic pattern.6 
• The goal of any extended release dosage form is to maintain therapeutic levels of the drug 
for an extended period of time.9 
• In extended release system, the amount and rate of drug release are determined by the 
physiological/therapeutic needs of the body and therefore provides physiologically, 
therapeutically based drug delivery system.6 
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Terminology 4 
 There are several terms used interchangeably for modified release dosage forms viz., 
controlled release, programmed release, prolonged release or sustained release, extended 
release, timed release, slow release, delayed release, repeat action, long acting, repository 
dosage forms etc.  
Modified Release  
 They are designed to modify the rate, the place or the timing of drug release and not 
absorption. The dosage forms are coated or uncoated.  
 Controlled Release 
               Controlled release systems provide a release profile predominantly controlled by the 
design of the system. 
  Prolonged Release or Sustained Release  
 These dosage forms only prolong the therapeutic blood or tissue level of the drug for an 
extended period of time that is not possible with conventional preparations. 
 Extended Release 
 Pharmaceutical dosage forms that release the drug slower than normal manner  
 Slow Release 
 Preparations formulated for the purpose of avoiding toxicity associated with peaking 
effect.  
 Delayed Release 
 These preparations release the drug after a “time delay” or after the tablet has passed 
through one part of the GI tract into another. All enteric coated tablets are delayed release 
tablets but not all delayed release tablets are enteric coated, because enteric- coated tablets 
release the drug rapidly once they reach the intestine and it cannot provide sustained therapy.  
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Repeat Action Tablet 
 In this one part of the tablet releases in the stomach, another part releases in the intestine. 
The release depends upon gastric emptying. It is an alternative to sustained release. Here 
multiple dose of a drug is retarded at a period interval.  
 Long Acting 
 They are used to encompass those drugs with an inherently long pharmacological effect 
because of their pharmacokinetic properties. Hence it can be seen that sustained release 
systems simply prolong the drug release, and hence plasma drug levels for an extended period 
of time, whereas controlled release systems control the release rate and the duration of actions. 
Advantages of Extended Release Products 4, 9, 10 
• Decreased local and systemic side effects.  
• Reduced gastrointestinal irritation.  
• Better drug utilization.  
• Reduction in the total amount of drug used.  
• Minimum drug accumulation and chronic dosing/improved efficiency in treatment.  
• Optimized therapy.  
• More uniform blood concentration.  
• Reduction in fluctuation in drug level and hence, more uniform pharmacological 
response.  
• Improved patient compliance.  
• Less frequent dosing  
• Reduced night time dosing  
• Reduced patient care time.  
Disadvantage of Sustained Release Products 4, 9, 10 
• Dose dumping  
• Reduced potential for accurate dose adjustment  
• Need for additional patient education.  
• Stability problems.  
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• Possible reduction in systemic availability.  
• Increased variability among dosage units.  
• Slow absorption may delay the onset of activity 
• Unpredictable and often poor in vitro, in vivo correlations 
• Reduced potential for dosage adjustment 
• Increased potential for first pass clearance and poor systemic availability 
• Effective drug release period is influenced and limited by GI residence time for oral 
controlled release formulations. 
 
Rationale for extended-release dosage forms 10 
Increase in time interval required between doses. This provides a reduction in the total 
number of doses required per day. Reduction in fluctuation of drug blood levels about the 
mean. A controlled release dosage form decrease the drug concentration’s fluctuation by, 
a) Reducing the blood levels(C max) thus potentially reducing dose related adverse 
effects  
b) Increasing the minimum plasma concentration (C min) thereby increasing efficacy if a 
threshold concentration is required. The plasma concentration stays within therapeutic 
range that is “therapeutic occupancy time”. 
 
Potential bioavailability problem of extended release products 10 
 The potential problems inherent in oral extended-release dosage forms related to 
• Interaction between the rate, extent and location that the dosage form release the drug 
• The regional differences in GI tract physiology. 
Characteristic That Makes a Drug Unsuitable For Extended- Release Formulation 10 
• Short elimination half-life,<2 hr 
• Long elimination half-life, >8 hr 
• Narrow therapeutic index 
• Large doses 
• Poor absorption 
• Active absorption 
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• Low or slow solubility 
• Time course of circulating drug different to that of pharmacological effect 
• Extensive first-pass clearance 
Extended release mechanism 3, 6 
The various systems under this category are    
• Dissolution controlled systems  
• Diffusion controlled systems  
• Dissolution and diffusion controlled systems  
• Ion exchange resin drug complexes  
• Slow dissolving salts and complexes  
• pH dependent formulations  
• Osmotic pressure controlled systems  
• Hydrodynamic pressure controlled systems   
Design and fabrication of controlled drug delivery systems 6 
  The majority of oral controlled release systems rely on dissolution, diffusion, or a 
combination of both mechanisms, to generate slow release of drug to the GI tract. Based on the 
data of drug candidate such as dose, rate constant for absorption and elimination, some 
elements of metabolism, physical and chemical properties one can estimate a desired release 
rate for the dosage form, the quantity of the drug needed and a preliminary strategy for the 
dosage form to be utilized. 
• Diffusion systems 6 
 In these systems the release rate of drug is determined by its diffusion through a 
water   insoluble polymer. There are two types of diffusion devices.  
 Reservoir devices 
 Matrix devices 
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Matrix devices 11 
 Depending upon the mechanism by which the rate controlling element controls diffusion 
such systems can be classified into five categories. 
o Hydrophobic Matrices (Plastic matrices) 
o Lipid Matrices 
o Hydrophilic Matrices 
o Biodegradable Matrices 
o Mineral Matrices 
Hydrophilic matrices 12 
         A hydrophilic matrix tablet is the simplest and most cost-effective method of fabricating 
an extended release solid oral dosage form. A typical ER matrix consists of a drug, one or 
more water swellable hydrophilic polymers and excipients such as fillers, binders, glidant and 
lubricant.  
Mechanism of drug release from the matrix 
 When the matrix tablet is exposed to an aqueous solution or gastrointestinal fluids, the 
surface of the tablet is wetted and the polymer hydrates to form a jelly-like structure 
around the matrix called as ‘gel layer’. This process is termed as glassy to rubber state 
transition of the polymer surface layer.  
 The gel layer grows with time as more water permeates into the core of the matrix, 
increasing the thickness of the gel layer and providing a diffusion barrier to the drug.  
 As the outer layer becomes fully hydrated, the polymer chains become completely 
relaxed leading to disentanglement and erosion from the surface of matrix.  
 Water continues to penetrate towards the core of the tablet, through the gel layer until it 
has been completely eroded.  
 Soluble drugs are released by this combination of diffusion and an erosion mechanism, 
erosion is the predominant mechanism for insoluble drugs. 
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Impact of the formulation and process variables on the drug release from extended 
release matrix systems 
Formulation variables 
• Drug particle size 
• Drug: polymer ratio 
• Polymer type 
• Fillers  
• Polymeric excipients 
Process variables 
• Compression force.  
• Tablet shape.  
• Tablet size.  
REGULATORY CONSIDERATION IN CONTROLLED RELEASE PRODUCTS 13  
FDA regulation of oral controlled-release drugs governing bioequivalence and in vitro–
in vivo correlations for controlled-release products requires the following pharmacokinetic 
evaluations,  
• Relative bioavailability following single dose 
• Relative bioavailability following multiple doses 
• Effect of food 
• Dose proportionality 
• Unit dosage strength proportionality 
• Single-dose bioequivalence study (experimental versus marketed formulations at 
various strengths) 
• In vivo–In vitro correlation 
• Pharmacokinetic/Pharmacodynamic (PK/PD) relationship. 
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In general, for drugs in which the exposure–response relationship has not been 
established or is unknown, applications for changing the formulation from immediate release 
to controlled release requires demonstration of the safety and efficacy of the product in the 
target patient population. When a drug is developed as a controlled-release dosage form, 
additional studies to characterize its absorption, distribution, metabolism, and excretion 
characteristics are recommended. 
 
IMMEDIATE RELEASE TABLETS 6 
 Immediate release tablets are designed to disintegrate and release the drug in absence of 
any controlling features such as coating or other formulation technique  
     Disintegrants are used to ensure that, when a tablet is ingested, it breaks down quickly 
in the stomach. Rapid disintegration is a necessary step in ensuring that the active ingredients 
are bioavailable and readily absorbed. This is especially important for immediate release 
products where rapid release of drug substance is aimed at. The proper choice of disintegrants 
and its consistency of performance are critical to formulation development of immediate 
release tablets. Some superdisintegrants are Croscaramellose sodium, Crospovidone, L-HPC 
(Low Substituted hydroxypropyl ether of cellulose), Sodium Starch Glycolate.6  
TABLET IN CAPSULE DOSAGE FORM14 
    Tablet in capsule is a multifunctional and multiple unit system, which contains versatile 
mini-tablets in a hard gelatin capsule.  
    It can be developed by preparing Rapid-release Mini-Tablets, Sustained-release Mini-
Tablets, Pulsatile Mini-Tablets, and Delayed-onset Sustained-release Mini-Tablets, each with 
various lag times of release and encapsulating in a capsule. 
The system can be designed to contain rapid and delayed release mini-tablets of two 
different or similar drugs. Two tablets in a capsule is suitable for sequential release of two 
drugs in combination, separate two incompatible substances, and also for sustained release 
drug delivery  in which one tablet in the capsule is immediate release as initial dose and second 
is maintenance dose. 
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 Biphasic delivery system can be achieved in this dosage form and it can produce the 
rapid onset of release for those drugs that need prompt appearance of therapeutic effect, 
followed by an extended release phase at a constant rate. When a simple constant rate of drug 
release does not entirely satisfy the therapeutic objective, the quick/ slow drug delivery system 
can be opted to achieve it. The nature of tablets and number of tablets to be filled depends on 
the formulator and the objective of the drug delivery system. 
                                       Fig 1.2: Tablet in Capsule System 
Source: Raghevendra Rao et al 2011 [43] 
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OBJECTIVE OF THE WORK 
 
1. To formulate a combination dosage form of Aceclofenac Extended Release Tablet         
200 mg and Misoprostol Immediate Release Tablet 200 mcg enclosed in Size ‘0’ 
elongated Hard Gelatin Capsules. 
2. Preformulation study shall be taken up to decide on the Drug – Excipient compatibility of   
 Aceclofenac and Misoprostol individually .15 
3. A compact Aceclofenac Extended Release Tablet 200 mg shall be prepared by using  
 varying grades of Hydrophilic polymer HPMC and Ceolus KG 1000 (Microcrystalline 
 cellulose). 
4. The dissolution profile of Aceclofenac ER tablets for a period of 12 hr and mechanism of     
     drug release from the ER tablet shall be determined.16 
5. A Misoprostol Immediate Release Tablet 200 mcg shall be prepared by direct 
 compression method. 
6. In process Quality Control Checks like Bulk Density, Tapped Density, Compressibility 
 Index, Hausner’s Ratio, Angle of Repose for the blend/granules and Uniformity of 
    weight, Thickness, Hardness, Friability, Disintegration Time shall be measured for 
 tablets of every formulation trial. 
7. Accelerated Stability Study of the combination product enclosed in capsule packed in  
 60cc HDPE Bottle and 33mm PP Child Resistant Cap, Induction sealed  with 1   
 g of 6 g/yard cotton as dunnage, shall be determined at the end of 40 ±2°C /75±5% RH 
 3rd  Month and the following shall be used as raiders for evaluation while  comparing 
 with Initial.                                                                                                                        
• Appearance  
• Assay  
• Thickness 
• Friability 
• Hardness    
• Dissolution  
• Disintegration Time 
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RATIONALE BEHIND THE FORMULATION 
• Aceclofenac therapy is effective, well-tolerated, widely accepted and of considerable                  
value to both the patient and physician in the management of inflammatory pain.17 
• It is prescribed for both acute and chronic inflammatory and degenerative disease such as 
osteoarthritis, rheumatoid arthritis with low incidence of side-effects.18 
• Advancing age is the powerful risk factor for osteoarthritis and rheumatoid arthritis. 
• NSAID for chronic use places patients at a risk for serious Gastroduodenal complications 
and in particular geriatric patients.19 
• Misoprostol is the only drug indicated for prevention of NSAID induced gastropathy.20 
• Combination of Aceclofenac and Misoprostol tablets in a simple Tablet in Capsule dosage 
yields added advantage. 
• It offers advantage in terms of Safety, Patient compliance, Ease of manufacturing and as  
Chronopharmacotherapy with maximum therapeutic effect and minimum side effects.16 
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LITERATURE REVIEW 
Literature  pertaining to the drugs  
Anil Pareek et al.21 compared the efficacy and safety of Aceclofenac control release (CR) 
tablets with conventional Aceclofenac tablets in patients with knee osteoarthritis (OA). This 
was a double-blind, double-dummy, randomized, parallel group multi-centric study conducted 
at 6 centers. It was observed in the study that patients on Aceclofenac group consumed more 
tablets of ranitidine as compared to patients on Aceclofenac-CR group indicates higher 
incidence of gastrointestinal adverse events. The results suggested that Aceclofenac-CR 
formulation was found to be effective and safe while offering practical advantage of once daily 
administration. 
 Ballinger AB et al.22 performed a study involving patients receiving NSAID. The study states 
that many NSAID associated ulcers that bleed or perforate have been asymptomatic until the 
time of presentation. It concluded that Misoprostol is the best choice for NSAID induced 
Gastroduodenal damage and it is superior to all other drugs in prevention of gastric damage. It 
also reveals that prophylactic treatment should be considered in at-risk patients. 
Davey PJ et al.23 conducted a study  that considered the cost effectiveness of Misoprostol 
prophylaxis for Nonsteroidal Anti-Inflammatory Drug  induced gastrointestinal damage, using 
data from the Misoprostol Ulcer Complications Outcomes Safety Assessment (MUCOSA) trial 
which involved 8843 patients receiving continuous NSAID therapy for  the control of 
Rheumatoid arthritis. This study concluded that cost effectiveness of Misoprostol  prophylaxis 
in  long-term Nonsteroidal Anti-Inflammatory Drug therapy such as arthritis. 
Dooley M et al.24 conducted a meta-analysis of 13 comparisons with Diclofenac, Naproxen, 
Piroxicam, Indomethacin, Tenoxicam or  Ketoprofen in 3574  patients, and preliminary details 
of a comparison with 10 other NSAIDs in 142,776 patients. Aceclofenac reduces joint 
inflammation, pain intensity and the duration of morning stiffness in patients with rheumatoid 
arthritis, and is similar in efficacy to Ketoprofen, Diclofenac, Indomethacin and Tenoxicam in 
these patients. Data from in vitro studies indicate properties of particular interest with respect 
to cartilage matrix effects and selectivity for cyclo-oxygenase-2and it is evident that 
Aceclofenac is well tolerated with improved  GI tolerability relative to other NSAIDs. 
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Fred E Silverstein et al.25 performed  6-month randomized, double-blind, placebo-controlled 
trial including 8843 men and women  with mean age of 68 years receiving continuous therapy 
with any of 10 specified NSAIDs for control of symptoms of rheumatoid arthritis. The study 
revealed that  serious upper gastrointestinal complications  including perforation, obstruction, 
and bleeding, in older patients  with rheumatoid arthritis were reduced by 40%  among  
patients  receiving Misoprostol compared with those receiving placebo. 
George V Papatheodoridis et al.26 studied that H. pylori infection almost doubled the risk of 
upper gastrointestinal bleeding among NSAID users after adjustment for other risk factors for 
bleeding. H. pylori infection was diagnosed by serum antibodies and CagA seropositivity. It 
was diagnosed by enzyme-linked immunoassay. 
Gérard Thiéfin et al.27 assessed the prevalence of gastroprotective agent prescription in 
patients treated with Nonsteroidal Anti-Inflammatory Drugs in France to analyze the 
determinants of this prescription. This study concluded that gastroprotection is still largely 
underprescribed in patients at risk of gastrointestinal Nonsteroidal Anti-Inflammatory Drug 
complications in France. And in geriatric population, half of Nonsteroidal Anti-Inflammatory 
Drug users above 65 years are prescribed with gastroprotective agents. 
Jay L Goldstein et al.20 reviewed the current approaches in prevention of NSAID-induced 
Gastropathy and economic implications of NSAID-induced Ulceration. It states that 
Misoprostol is the only drug currently indicated for the prevention of NSAID-induced 
gastropathy. The review concluded that increasing proportion of elderly, inherently at-risk 
patients in the population, increased savings can be realized with the use of a GI-protective 
NSAID such as Diclofenac/misoprostol combination. 
Lemmel EM et al.17 conducted a pan-European study involving 23407 patients with pain due 
to various inflammatory or degenerative rheumatic diseases was undertaken in Austria, 
Belgium, Germany and Greece, to evaluate overall pain relief and satisfaction with 
Aceclofenac therapy. The study concluded that Aceclofenac was considered by patients to be a 
highly efficacious treatment with excellent and fast analgesic activity that was maintained 
throughout the study period. Patient satisfaction compliance of Aceclofenac therapy was found 
to be 90% at the end of the study. 
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Li J et al.28 studied that Misoprostol, a PGE2 receptor agonist that is utilized clinically as an 
anti-ulcer agent and signals through the protective PGE2 EP2, EP3, and EP4 receptors, would 
reduce brain injury in the murine middle cerebral artery occlusion-reperfusion (MCAO-RP) 
model. These findings suggest a novel function for Misoprostol as a protective agent in 
cerebral ischemia acting via the PGE2 EP2 and/or EP4 receptors. 
Plosker GL et al.29 studied that the combined formulation of Diclofenac/Misoprostol provides 
effective relief of pain and inflammation, with a 2- to 3-fold lower incidence of NSAID-
associated gastroduodenal ulcers than Diclofenac monotherapy. This study also included 
pharmacoeconomic studies of co-prescribed Misoprostol with NSAIDs, the most favourable 
results with the combined formulation of Diclofenac/Misoprostol appear to be in patients at 
high risk of developing NSAID-associated gastroduodenal ulcers such as elderly with 
rheumatoid arthritis or osteoarthritis. 
Literature pertaining to the formulation 
Afsar C Shaikh et al.30 developed sustained release tablets of Aceclofenac by wet granulation 
using hydrophilic polymers HPMC K100 and HPMC K15. In vitro dissolution studies were 
performed using 0.1 N Hydrochloric acid pH 1.2 and phosphate buffer pH 6.8. The kinetics of 
the release process of drug in the selected formulation was studied using Higuchi and 
Korsmeyer‐Peppas models. Results indicated that formulation of sustained release tablet of 
Aceclofenac containing HPMC K100 as retarding agent fulfills all the requirement of sustained 
release tablet. 
Ahmed A Bosela et al.31 developed a multifunctional multiple unit system for programmable 
release for combined administration of rapid and delayed release minitablets of Famotidine 
with timed release tablets of Ketorolac in novel tablet- in- capsule dosage form. Famotidine 
was included as two mini tablets one release rapidly and other after a lag time of 6 hours. For 
Ketorolac the water soluble tromethamine salt was used to develop mini tablets providing a 
pulse of drug release after 1 hour with the other mini tablet providing sustained drug release 
after a lag time of 4 hours. This combination provides sustained analgesic effect of Ketorolac 
with sustained gastric protection of Famotidine. 
Basak SC et al.32 formulated and studied controlled release HPMC matrix tablets of 
Propranolol hydrochloride. The matrix tablets were prepared with HPMC K4M and fulfilled all 
the official requirements of tablet dosage forms. The in vitro drug release was measured in 
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aqueous solutions for a period of 12 hours using 1.2 pH buffer for first hour and pH 7.5 buffer 
for the rest of periods. The drug release was within the limits of USP requirements. 
Bin Li et al.33 developed a programmed drug delivery from a novel system, which contains a 
water-soluble cap, impermeable capsule body, and two multi-layered tablets. In this study the 
multi-layered tablets formulation prepared was filled within the capsule body and sealed with 
the water-soluble cap. Sodium alginate and HPMC E5 were used as the candidate modulating 
barrier material. This study investigated the effect of types of barrier materials, weight of 
barrier layer, tablets hardness, location of tablets in capsule, and bulking agent on release 
profiles. 
David Chen et al.34 formulated the sustained-release solid dispersion of Misoprostol using 
Ammonio Methacrylate copolymer Eudrgit RS, RL. The solid dispersion matrix formed by the 
copolymer protects Misoprostol from being degraded by water so that the stability of 
Misoprostol is improved. The formulated dispersion found to release Misoprostol slowly by 
diffusion from the copolymer matrix and give sustained effect. This revealed that Misoprostol–
Eudragit dispersion can be used in a powder form, filled in capsules, or compressed into tablets 
for sustained delivery of Misoprostol. 
James L Ford et al.35 studied the release rate of Promethazine hydrochloride from HPMC 
tablet matrices. The results stated that rate of release was controlled predominantly by drug-
polymer ratio and the viscosity of the polymer. It concluded that lowest viscosity HPMC 
produced higher release rates than other HPMC polymers. The Molecular size of the polymers 
did not produce much influence on rate of release.  
Jigar Mehta et al.36 developed and validated the in vitro dissolution method with HPLC 
analysis for Misoprostol in formulated dosage form. The study finalized that paddle at 50rpm 
stirring speed, deaerated water dissolution medium with volume 500mlas per very low content 
of the drug substance and drug product.  
Karali TT et al.37 studied that stability of Misoprostol oil is significantly improved in HPMC 
dispersion. The results states that below 30% relative humidity (approximately 2% water) the 
Misoprostol degradation were found to be minimum when it is in the form of 1:100 HPMC 
dispersion.                                                          
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Oth M et al.38 developed a Bilayer floating dosage unit to achieve local delivery of 
Misoprostol, at the gastric mucosa level. The unit was a capsule consisting of a floating layer 
maintaining the dosage unit buoyant upon the gastric content and a drug layer formulated to act 
as a sustained-delivery system. HPMC was used to make hydrophilic matrix. The present study 
also revealed that the use of a large capsule increases the gastric residence time, as it impedes 
passage through the pylorus opening. Gamma-Scintigraphic studies were used for evaluations. 
Indiran Pather S et al.39 took an effort to reduce production costs by direct compression of 
theophylline and ethyl cellulose. This method enabled to sustain the release of a therapeutic 
dose of theophylline over a 12 hr period. The study states that Theophylline to ethylcellulose 
ratio and the tablet hardness were found to influence the rate of drug release. The study 
concluded that the rate of drug release can be altered by changing the ratio of theophylline to 
ethylcellulose and by adjusting the compression force used to prepare the tablets. 
Patil Dinesh et al.40 developed a multifunctional and multiple unit system containing  
Propranolol hydrochloride sustained release pellets and Flunarizine dihydrochloride immediate 
release mini tablet in a hard gelatin capsule for synergistic effect in migraine and hypertension. 
In vitro dissolution study was performed separately. Propranolol hydrochloride  sustained 
release pellets in pH 1.2 phosphate buffer for 1.5 hours followed by testing in pH 6.8 buffer at 
4,8,14 & 24 hours and Flunarizine dihydrochloride immediate release tablets separately in 
different medias 0.1 N HCl, pH 4.5, 6.8 and water at 60 minutes. 
Raghavendra Rao NG et al.41 develop sustained release matrix tablets of water soluble 
Tramadol hydrochloride using different polymers HPMC, Karaya gum and Carrageenan. The 
effect of polymer concentration and polymer blend concentration were studied by employing 
different ratios of polymers. The in vitro release study was performed in 0.1 N Hcl pH 1.2 for 2 
hrs and in phosphate buffer pH 6.8 up to 12 hrs. The results showed that 20% HPMC K15M 
and 80% of carageenan release the drug which follows Zero order kinetics and was comparable 
with release rate of the marketed product. 
Punna Rao Ravi et al.42 formulated the oral controlled release matrix tablets of Lamivudine 
using HPMC as the retardant polymer. The effect of various formulation factors such as 
polymer proportion, polymer viscosity, and compression force on the in vitro release of drug 
was studied. In vitro release studies revealed that the increase in polymer proportion and 
viscosity grade and increase in compression force was found to decrease the rate of drug 
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release. Formulations containing 60% HPMC 4000 cps were found to show good initial release 
and extended the release up to 16 hrs while tablets containing 80% HPMC 4000 cps and 60% 
HPMC 15 000 cps showed a first-hour release of 22% but extended the release up to 20 hours. 
Raghavendra Rao NG et al.43 developed a system comprises of different doses of immediate 
release tablets and sustained release tablets of Montelukast sodium contained in a HPMC 
capsule. Two immediate release and three sustained release tablets were used to obtain 
different drug release rates. In vitro evaluation showed that the drug contained in the 
immediate release tablets dissolved within the first 45 min, and the drug contained in the 
sustained release tablets formulated using HPMC released over a period of 10 to 12 hrs. The 
study states that this multiparticulate delivery system offers chronotherapeutic advantage in 
nocturnal asthma. 
Shinichiro Tajiri et al.44 developed two types of extended-release tablets of cevimeline simple 
matrix tablets and press-coated tablets and assessed their potential as extended-release dosage 
forms. The results showed that simple matrix tablets could not sustain the release of cevimeline 
while the press-coated tablets showed a slower dissolution rate compared with simple matrix 
tablets and the release curve was nearly linear. The results concluded that cevimeline was 
constantly released from the press-coated tablets in the gastrointestinal tract and the steady-
state plasma drug levels were maintained in beagle dogs. 
Santanu Ghosh et al.45 developed  matrix tablets for oral controlled release of Aceclofenac  
using various viscosity of hydrophilic polymer HPMC in two different proportions and ethyl 
cellulose and Guar gum were prepared by wet granulation method. In vitro dissolution studies 
were performed for 0-12 hrs. The dissolution medium was phosphate buffer 7.5. It was found 
that the in vitro dissolution profile of Aceclofenac is almost similar with that of marketed 
product. The kinetics of the release process of drug in the formulations were studied using 
different dissolution models. The finalized formulation followed Higuchi model. 
Syed Azeem Hyder et al.46 attempted to increase the rate of dissolution of Rupatidine by using 
superdisintegrants CMC, crospovidone and alginic acid. 32 full factorial design was used to 
investigate the joint influence of 2 independent variables: amount of selected superdisintegrant  
crospovidone and hardness of the tablets. The results of multiple linear regression analysis 
revealed that the dependent variables disintegration time and drug release at 0.5h values are 
strongly dependent on the selected independent variables.  
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Sharma et al.47 developed a mouth dissolving tablets of Domperidone containing camphor and 
crospovidone by direct compression technique. A 32 full factorial design was used to 
investigate the joint influence of two formulation variables, amount of camphor and 
crospovidone. The results suggested that tablets should be prepared using an optimum 
concentration of camphor and high concentration of crospovidone 
 Shivakumar HN et al.48 formulated a pH-sensitive tablet in capsule system intended to 
approximate the Chronobiology of nocturnal asthma and for site specific release to the colon. 
Drug-loaded core minitablets were produced by wet granulation procedure using alcoholic 
solution of PVP K 30 as a binder and coated using Eudragit S-100 to produce the pH sensitive 
minitablets. The studies showed that a Eudragit S-100 coat weight of 10% weight gain was 
sufficient to impart an excellent gastro resistant property to the tablets for effective release of 
the drug at higher pH values. 
Umesh D Shivhare et al.49 formulated sustained release once daily tablets of Aceclofenac by 
wet granulation using carboxy polymethylene polymer. In vitro dissolution studies were 
performed using phosphate buffer 6.8. Formulations containing Carbopol 971P and Carbopol 
974P were found to release the drug in sustained manner upto 24 hour. Different dissolution 
models were applied to evaluate drug release mechanism and kinetics and the hydrophilic 
matrix tablets formulated. 
Ying-huan Li et al.14  developed a  multifunctional and multiple unit system, which contains 
different mini-tablets such as Rapid-release Mini-Tablets, Sustained-release Mini-Tablets, 
Pulsatile Mini-Tablets, and Delayed-onset Sustained-release Mini-Tablet in a hard gelation 
capsule, each with various lag times of release. Based on the combinations of mini-tablets, 
multiplied pulsatile drug delivery system, site-specific, slow/quick, quick/slow, and zero-order 
drug delivery system could be obtained. Nifidipine was used as the model drug. 
Literature pertaining to the excipients  
Hardy IJ et al.50 studied modulation of drug release kinetics from HPMC matrix tablets using 
PVP. The study presents a simple, cost effective and elegant solution for achieving a range of 
predictable release profiles from linear to bimodal for a water-soluble drug (Caffeine) form 
HPMC matrices through the inclusion of PVP. Mechanistic studies using gel rheology, 
excipient dissolution and near infrared microscopy are presented which shows the modulation 
of drug release. 
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Harris Shoaib M et al.51 studied the evaluation of drug release kinetics from Ibuprofen matrix 
using HPMC. Different dissolution models were applied to evaluate drug release mechanism 
and kinetics. The drug release data fit well to the Higuchi expression. Drug release mechanism 
as a complex mixture of diffusion, swelling and erosion. 
Khanvilkar KH et al.52 studied the effects of use of a mixture of two different grades of 
HPMC, apparent viscosity and tablet hardness on drug release profiles of extended-release 
matrix tablets. A 2(3) full factorial design was used. Dissolution studies were performed in 
USP apparatus I and t50%, t lag values are used for evalution of matrix tablets. The study 
concluded that within the viscosity range studied (12,000-19,500 cps) an HPMC mixture of 
two viscosity grades can be substituted for another HPMC grade if the apparent viscosity is 
comparable. And the drug release is diffusion-controlled and depends mostly on the viscosity 
of the gel layer formed. 
Melanie Dumarey et al.53 studied the influence of microcrystalline cellulose properties on the 
roll compaction process. Four dissimilar MCC grades were selected for study. It confirmed that 
the particle size increase caused by roll compaction is highly responsible for the tensile 
strength decrease of the tablets. The evaluation of the full factorial design shows that the 
Ceolus KG-1000 resulted in tablets with higher tensile strength and shorter disintegration time, 
compared to the other MCC grades. 
Mira Jivraj et al.54 studied that many formulation scientists ranked microcrystalline cellulose 
as the most useful filler for direct compression. It reveals that the popularity ascribed to its 
excellent compactibility at low pressures, high dilution potential and superior disintegration 
properties. This study concluded that as a result of its low bulk density, microcrystalline 
cellulose has a high dilution potential. 
Obae K et al.55 made  attempt  to fractionate microcrystalline cellulose particles of Avicel® 
PH-101 and Ceolus® KG-801 into four sieve fractions by using an air-jet sieve and to disclose 
effects of morphology of the particle on tablet tensile strength. It increased with an increase in 
the ratio of L:D for particles (L- length: D- width). KG grade consists of a larger number of 
rod-shaped particles than PH grade, giving significantly higher compressibility than PH grade. 
It also revealed that the hardness of tablets made of the KG grade is about 1.5 times higher 
than that of the standard PH grade, but both tablets can be disintegrated easily within the same 
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short period once they come in contact with water. This study concluded that the high 
compressibility of KG grade enables to improve the tensile strength of tablets. 
Ranjani V Nellore et al.56 developed model extended-release matrix tablet formulations for 
Metoprolol tartrate. Different grades of HPMC K4M, K15M, K100M and K100LV were used. 
Three granulation processes were employed for the preparation of tablets. In vitro drug release 
testing was performed in pH 6.8 phosphate buffer using USP apparatus type II at 50 rpm. The 
study results suggested that HPMC K100LV can be used as the hydrophilic matrix polymer 
and fluid-bed granulation as the process of choice for further evaluation of critical and non-
critical formulation and processing variables. 
Takumi Magome et al.57 compared the tableting properties of Ceolus KG-1000 with other 
microcrystalline cellulose products in roller compaction using an acetaminophen formulation. 
In this comparison Microcrystalline cellulose products used were Ceolus KG 1000, Ceolus KG 
802, and Ceolus PH 101. Roller compaction was done at 15 kN 30 kN and 50kN. When the 
roller compaction force increased, the tablet hardness decreased with other grades while tablets 
with KG-1000 could only keep around 50 N that is considered as practically required hardness.  
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MARKETED FORMULATIONS 58-62 
ACECLOFENAC 
TRADENAME STRENGTH DOSAGE FORM MANUFACTURER 
Indian brands 
Valus –A 100mg Tablet Glenmark 
Aroff 100mg Film coated tablet Unichem 
Fastanac SR 200mg Sustained release tablet Lupin 
Aceclo 200mg Sustained release FC tablet Aristo 
Zerodol CR 200mg Controlled release tablet IPCA 
Zynac 150mg/ml Injection Zydus 
International brands 
Preservex 100mg Film coated tablets Almirall ltd 
Airtal 100mg Tablet Highnoon 
Bristaflam 100mg Oral powder Bristoll Mayer Squibb 
 
COMBINATION PRODUCTS OF ACECLOFENAC  
 
TRADE 
NAME COMBINATION AND STRENGTH 
DOSAGE 
FORM MANUFACTURER 
Altra day 
Aceclofenac 200mg, 
 Rabeprazole 20mg 
Spantules Inventia 
Altraflam-P 
Aceclofenac 100mg , 
Paracetamol 500mg 
Tablets Ranbaxy 
Peale 
Aceclofenac 1.5%w/w , Methyl 
Salycilate 105w/w,  Oleum lini 3% 
w/w,  Menthol 5% w/w, Capsaicin 
0.01%w/w,  Benzyl alcohol 1% w/w 
Gel Cadila 
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 MISOPROSTOL 
TRADE NAME STRENGTH DOSAGE FORM MANUFACTURER 
Indian Brands 
Misoprost  Misoprostol 25, 100, 200mcg  Tablet  Cipla  
Prestakind  Misoprostol 200mcg Tablet  Mankind  
Misolast  Misoprostol 200mcg Tablet  FDC 
International brands 
Cytotec Misoprostol 200mcg Tablet  GD Searle LLC 
Cyprostol  Misoprostol 200mcg Tablet  Idis  
Gymiso Misoprostol 200mcg Tablet  HRA Pharma 
Apo-Misoprostol Misoprostol 100, 200mcg Tablet  Apotex  
Misotrol  Misoprostol 200mcg Tablet  Sanofi Aventis  
 
COMBINATION PRODUCTS OF MISOPROSTOL 
TRADE 
NAME 
COMBINATION AND STRENGTH 
DOSAGE 
FORM 
MANUFACTURER 
Arthotec  Misoprostol 200mcg,  
Diclofenac 50, 75mg  
Tablet  GD Searle LLC 
Artene  Misoprostol 200mcg,  
Diclofenac  150mg  
Tablet  Merck  
Misonac  Misoprostol 200mcg,  
Diclofenac 50, 100mg  
Tablet  Ordain Health care 
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DRUG PROFILE63-70 
Drug name   :  Aceclofenac 
Chemical name  :  [[[2-[(2, 6-Dichlorophenyl) amino] phenyl] acetyl] oxy] acetic acid. 
Synonym     : Aceclofenaco,Aceclofenacum,aceclofenakas 
CAS number   : 89796-99-6 
Mol.formula   :  C16H13Cl2NO4 
 
Mol.weight    :  354.2 
 
Melting point   : 149° to 150° C 
 
Origin of substance  :  Synthetic  
 
Structure  :                           
 
                                             
 
Category    :  Non Steroidal Anti-Inflammatory Drug 
  
Solubility     : It is practically insoluble in water, soluble in alcohol, 
                                    freely soluble in Acetone and dimethyl formamide. 
 
Proprietary names  : Airtal, Barcan, Biofenac, Difucrem, Falcol, Gerbin, Preservex, Sanein.                   
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CLINICAL PHARMACOLOGY 
Mechanism of action  
 Aceclofenac relieves pain and inflammation through a variety of mechanisms and in 
addition exerts stimulatory effects on cartilage matrix synthesis. 
 Anti-Inflammatory activity 
  The anti-inflammatory effects of Aceclofenac have been shown in both acute and chronic 
inflammation. It inhibits various mediators of pain and inflammation including, 
 
•  PGE2 via cyclooxygenase inhibition (COX-1 & COX-2) after intracellular metabolism            
to 4- hydroxy-aceclofenac and Diclofenac in human rheumatoid synovial cells and other 
inflammatory cells.  
•  IL-1β, IL-6 and tumor necrosis factor in Human Osteoarthritic Synovial cells and 
human articular chondrocytes.  
•  Reactive oxygen species (which plays a role in joint damage) has also been observed in 
patients with osteoarthritis of knee.  
•  Expression of cell adhesion molecules (which is implicated in cell migration and 
inflammation) has also been shown in human neutrophils.  
 
Stimulatory effects on cartilage matrix synthesis  
 Aceclofenac stimulates glycosaminoglycan synthesis in human osteoarthritic cartilage by 
inhibition of IL-1β and suppresses cartilage degeneration by inhibiting IL-1β mediated 
promatrix metalloproteinase production and proteoglycan release.  
 
PHARMACOKINETICS 
Absorption 
 Aceclofenac is absorbed rapidly and completely after oral administration. Peak plasma 
concentrations are reached approximately 1-3 hours after an oral dose. The presence of food 
does not alter the extent of absorption of Aceclofenac but the absorption rate is reduced. 
 
Drug Profile 5 
 
31 Department of Pharmaceutics, Madras Medical College 
 
Distribution 
 Aceclofenac is highly protein bound (~99.7%). The plasma concentration of Aceclofenac 
was approximately twice that in synovial fluid and multiple doses of drug in patients with knee 
pain and synovial fluid effusion. The volume of distribution is approximately 30L. 
Metabolism 
 Aceclofenac is metabolized into a major metabolite, 4- hydroxy Aceclofenac and to a 
number of other metabolites including 5-hydroxy Aceclofenac, 4- hydroxy Diclofenac, and 5- 
hydroxy Diclofenac. These other metabolites account for the fate of approximately 20% of 
each dose of Aceclofenac. 
Excretion 
 Renal excretion is the main route of elimination of Aceclofenac with 70-80% of the 
administered dose found in the urine, mainly as the glucuronides of Aceclofenac and its 
metabolites. Of each of dose of Aceclofenac, 20% is excreted in the faeces. The plasma 
elimination half-life of the drug is approximately 4 hours. 
Indications 
 Aceclofenac is indicated for the relief of pain and inflammation associated with 
Rheumatoid arthritis, Osteoarthritis and in Ankylosing spondylitis. 
Contraindications 
 Aceclofenac should not be administered to patients hypersensitive to Aceclofenac or 
other NSAID’s, or patients with history of Aspirin or NSAID’s related allergic and to patients 
with anaphylactic reactions or with peptic ulcers or GI bleeding, moderate of severe renal 
impairment. 
Drug interactions 
 Drug interactions associated with Aceclofenac are similar to those observed with other 
NSAID’s. Aceclofenac may increase plasma concentrations of Lithium, Digoxin and 
Methotrexate, increase the activity of anti coagulants, inhibit activity of Diuretics, enhance 
Cyclosporine Nephrotoxicity and precipitate convulsions when co administered with 
Quinolone antibiotics. The co-administration of Aceclofenac with other NSAID’s or 
corticosteroids may result in increased frequency of adverse events. 
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Adverse drug reactions 
 Aceclofenac is well tolerated with most adverse events being minor and reversible and 
affecting mainly the GI system. Most common events includes dyspepsia, and abdominal pain, 
dizziness, vertigo, pruritis, rash and dermatitis have been reported with Aceclofenac, but the 
incidence of these events is less than 5%. Increased blood urea nitrogen and blood creatinine 
level have been reported with Aceclofenac treatment. As with other NSAID’s, Aceclofenac can 
elevate circulating levels of hepatic enzymes. 
 
Dose and Administration 
 The usual dose of Aceclofenac is 100mg given orally twice daily. There is some evidence 
that the dose of Aceclofenac should be reduced in patients with hepatic impairment and it is 
suggested that an initial daily dose of 100mg be used. 
 
Over dosage 
 There are no human data available on the consequences of Aceclofenac over dosage. The 
symptoms could be nausea, vomiting, stomach pain, dizziness, somnolence, and headache. 
 
Therapeutic Uses 
 Aceclofenac is used in   
 Osteoarthritis 
 Rheumatoid arthritis 
 Ankylosing spondylitis 
 Dental pain 
 Postoperative pain 
 Dysmenorrhoea 
 Acute lumbago 
 Musculoskeletal trauma 
 Gonalgia (knee pain) 
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Drug name  : Misoprostol 
Chemical name :  (11α,13E)-11,16-Dihydroxy–16–methyl–9–oxoprost–13–en–1–oic acid   
                                    methyl ester                    
Synonym   : Misoprostolum, Mizoprostol  
CAS number : 59122-46-2 
Mol.formula : C22H38O5 
   
Mol.weight  : Average: 382.5341       
                                 Monoisotopic: 382.271924326 
 
Origin of substance:  Synthetic  
 
Structure                 :                           
 
 
Categories   :   Anti-Ulcer Agents 
                           Oxytocics 
                                     Nonsteroidal Abortifacient Agents 
                           Prostaglandins 
Solubility               : Water-soluble, Viscous liquid 
 
Proprietary names  : Cytotec, Arthrotec (with Diclofenac), Napratec (with Naproxen) 
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CLINICAL PHARMACOLOGY 
Mechanism of action 
The significant Cytoprotective actions of Misoprostol are related to several mechanisms. These 
include,  
 Increased secretion of bicarbonate, 
 Considerable decrease in the volume and pepsin content of the gastric secretions,  
 It prevents harmful agents from disrupting the tight junctions between the epithelial 
cells  which stops the subsequent back diffusion of H+ ions into the gastric mucosa,  
 Increased thickness of mucus layer, 
 Enhanced mucosal blood flow as a result of direct vasodilatation, 
 Stabilization of tissue lysozymes/vascular endothelium,  
 Improvement of mucosal regeneration  capacity, and  
 Replacement of prostaglandins that have been depleted as a result of various insults to 
the area. Misoprostol has also been shown to increase the amplitude and frequency of 
uterine contractions during pregnancy via selective binding to the EP-2/EP-3 prostanoid 
receptors. 
 
PHARMACOKINETICS 
Absorption       : Misoprostol is extensively absorbed. Approximately 88% of a dose is  
                   absorbed. 
Tmax                            : 12 ± 3 min 
 Half life       : Misoprostol, less than 30 min, Misoprostol acid 20 min  
 Volume of distribution  : Approximately 6.6 L/kg 
 Metabolism   : It undergoes rapid de-esterification to its free acid, which is                     
 responsible for its clinical activity. The alpha side chain undergoes 
 beta oxidation and the beta side chain undergoes omega oxidation 
 followed by reduction of the ketone to give prostaglandin F 
 analogs. 
 Protein binding       : 85% (the free acid of Misoprostol) 
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Route of Elimination  
 Excreted mainly via urine as its dimer and tetramer (65%) and some in faeces (15%) . 
Excretion is mainly in the form of metabolites but little as the unchanged drug. After a single 
oral dose of Misoprostol to nursing mothers, Misoprostol acid was excreted in breast milk. 
Indications  
 Treatment of ulceration (duodenal, gastric and NSAID induced) and prophylaxis for 
NSAID induced ulceration. 
 Misoprostol is indicated for the medical termination of an intrauterine pregnancy, used 
alone or in combination with Methotrexate, as well as the induction of labour in a 
selected population of pregnant women with unfavourable cervices.  
 Misoprostol is used for the prevention, treatment of serious postpartum hemorrhage. 
 
PHARMACODYNAMICS  
 Misoprostol is a prostaglandin E1 (PGE1) analogue used for the treatment and prevention 
of stomach ulcers. When administered,  
 Misoprostol stimulates increased secretion of the protective mucus and increases 
mucosal blood flow, thereby increasing mucosal integrity.  
 Misoprostol seems to inhibit gastric acid secretion by a direct action on the parietal 
cells through binding to the prostaglandin receptor. 
 The activity of this receptor is mediated by G proteins which normally activate 
adenylate cyclase. The indirect inhibition of adenylate cyclase by Misoprostol may be 
dependent on guanosine-5’-triphosphate (GTP). 
Dosage and administration 
 The recommended adult oral dose of Misoprostol for reducing the risk of NSAID-
induced gastric ulcers is 200 mcg four times daily with food. It should be taken for the duration 
of NSAID therapy as prescribed by the physician. It should be taken with a meal, and the last 
dose of the day should be at bedtime.  
Adverse reactions 
 Gastrointestinal adverse events such as diarrhoea and abdominal pain, the incidence of 
diarrhea can be minimized by administering after meals and at bedtime, and by avoiding co-
administration of  Misoprostol with magnesium-containing antacids. Gynecological disorders 
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such as spotting (0.7%), cramps (0.6%), hypermenorrhea (0.5%), menstrual disorder (0.3%) 
and dysmenorrhea (0.1%), Postmenopausal vaginal bleeding. 
 
Warnings  
  Misoprostol administration to pregnant women can cause abortion, premature birth, or 
birth defects, Uterine rupture. It should not be taken by pregnant women to reduce the risk of 
ulcers induced by NSAID. It should not be used for reducing the risk of NSAID-induced ulcers 
in women of childbearing potential unless the patient is at high risk of complications from 
gastric ulcers associated with use of the NSAID, or is at high risk of developing gastric 
ulceration. In such patients, Misoprostol may be prescribed if the patient 
 Has had a negative serum pregnancy test within 2 weeks prior to beginning therapy.  
 Is capable of complying with effective contraceptive measures.  
 Has received both oral and written warnings of the hazards of Misoprostol, the risk of 
possible contraception failure, and the danger to other women of childbearing potential 
should the drug be taken by mistake.  
 Will begin Misoprostol only on the second or third day of the next normal menstrual 
period.  
 
Precautions 
 Caution should be employed when administering Misoprostol to patients with pre-
existing cardiovascular disease. Women of childbearing potential using Misoprostol to 
decrease the risk of NSAID-induced ulcers should be told that they must not be pregnant when 
Misoprostol therapy is initiated, and that they must use an effective contraception method. 
 
Special precautions 
 Adjustment of the dosing schedule in renal impaired patients is not routinely needed,   
but dosage can be reduced if the 200mcg dose is not tolerated. 
 There were no significant differences in the safety profile of Misoprostol in 
approximately 500 ulcer patients who were 65 years of age or older compared with 
younger patients.                   
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EXCIPIENT PROFILE53, 55, 57, 71-73 
MICROCRYSTALLINE CELLULOSE72 
Nonproprietary Names 
BP, JP   : Microcrystalline cellulose 
PhEur    : Cellulosum  microcristallinum 
USP-NF : Microcrystalline cellulose 
Synonyms 
 Avicel PH, Celex, cellulose gel, Celphere, Ceolus KG, Crystalline Cellulose, E460, 
Emcocel, Ethispheres, Fibrocel, Pharmacel, Tabulose, Vivapur. 
Chemical Name and CAS Registry Number 
 Cellulose [9004-34-6] 
Functional Category 
 Adsorbent, Suspending agent, Tablet and Capsule diluent, Tablet disintegrant. 
Applications in Pharmaceutical Formulation 
As a binder/diluent in oral tablet and capsule formulation in both wet-granulation and   
direct-compression processes. 
Table 7.1: Application of Microcrystalline cellulose 
Use Concentration (%) 
Adsorbent 20–90 
Antiadherent 5–20 
Capsule binder/diluents 20–90 
Tablet disintegrant 5–15 
Tablet binder/diluents 20–90 
 
Table 1.2: Typical Properties of  MCC 
Angle of 
Repose 
Density(g/cm3) Flowablity Melting Point                 
      °C 
Moisture  
content Bulk Tapped True 
49° 0.337 0.478 1.512-    
1.668 
1.41g/s 260-280 < 5%w/w 
Excipient profile 7 
 
38 Department of Pharmaceutics, Madras Medical College 
 
Solubility    : Slightly soluble in 5% w/v sodium hydroxide solution, practically insoluble in       
water, dilute acids and most organic solvents. 
Incompatibilities 
 Cellulose acetate is incompatible with strongly acidic or alkaline substances. Cellulose 
acetate is compatible with the following plasticizers diethyl phthalate, polyethylene glycol, 
triacetin, and triethyl citrate. 
Stability and Storage Conditions 
 Microcrystalline cellulose is a stable though hygroscopic material. The bulk material 
should be stored in a well-closed container in a cool, dry place. 
Uniqueness of Ceolus KG 100071, 73 
• Distinguished by its rod-form particle configuration which aids inter-particle cohesion 
when compression force is applied, resulting in twice the compactibility of conventional 
MCC. 
•  This enables tablets of equivalent hardness to be produced with lower compression force 
and less excipient than would conventionally be required. 
• Posses the largest L/D ratio when compared to other grades  KG-1000: 3.5, KG-802: 2.8, 
PH-101: 1.8 
• The particles are porous, rounded composites of multiple micro-rods. The result is an 
unparalleled combination of compressibility and flowability. 
• Heightened efficiency in direct-compression tableting with gravity feeder 
• Decreased capping  
• Enhanced  tabletting efficiency 
 The advantages of Ceolus KG 1000 are 73 
• Smaller tablet size make large-dose drugs without increasing tablet size, and to make small, 
easy-to-swallow tablets for seniors 
• Tabletting at low compression force  enables tabletting of drugs which are sensitive to loss 
of activity due to heat generated during compression 
• Reduced tablet breakage and fragmentation improves  productivity by lowering production 
loss 
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HYPROMELLOSE72 
Nonproprietary Names 
BP, USP      : Hypromellose 
JP        : Hydroxypropylmethylcellulose 
PhEur   : Hypromellosum 
Synonyms 
 Benecel MHPC, E464, hydroxypropyl methylcellulose, HPMC, Methocel, 
methylcellulose propylene glycol ether, methyl hydroxypropylcellulose, Metolose, Tylopur. 
Chemical Name and CAS Registry Number 
 Cellulose hydroxypropyl methyl ether [9004-65-3] 
Functional Category 
 Coating agent,film-former, rate-controlling polymer for sustained release, stabilizing 
agent, suspending agent, tablet binder, viscosity-increasing agent. 
Applications in Pharmaceutical Formulation 
 Hypromellose is widely used in oral, ophthalmic and topical pharmaceutical 
formulations.  
   Table 7.3: Application of Hypromellose  
Concentration Application 
2-5% Tablet binder 
2-20% Film-coating material 
10-80% Matrix extended release tablet 
 
Table 7.4: Typical Properties of Hypromellose 
Acidity/Alkailinity 
(1% w/w aq.solution) Ash 
Density(g/cm3)        Melting  
     Point ° C 
Moisture 
content Bulk Tapped True 
 
pH 5.5-8 
 
1.5-3 
 
0.341 
 
0.557 
 
1.326 
 
225-230 
Depends on 
RH and 
temperature 
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Solubility     
• Hypromellose is soluble in cold water 
• It is also soluble in mixtures of ethanol and dichloromethane, mixtures of methanol and   
dichloromethane, and mixtures of water and alcohol 
• Practically insoluble in  chloroform, ethanol (95%), and ether 
 
Specific gravity  : 1.26 
Viscosity of Hypromellose Grades 
 2% w/v aqueous solutions of Hypromellose are measured at 20 °C 
Table 7.5: Viscosity of different grades of Hypromellose 
Nominal Viscosity of HPMC in mPa s 
K100 LV CR K4 CR K15 CR K100M CR E50 
80-120 3000-5600 11250-21000 80000-120000 50 
 
Stability and Storage Conditions 
 Solutions are stable at pH 3–11. Aqueous solutions are liable to microbial spoilage and 
should be preserved with an antimicrobial preservative. Hypromellose powder should be stored 
in a well-closed container, in a cool, dry place. 
Incompatibilities 
 Hypromellose is incompatible with some oxidizing agents. 
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STEARIC ACID72 
Nonproprietary Names 
BP, JP, USPNF : Stearic acid 
PhEur       : Acidum stearicum 
 
Synonyms 
 Cetylacetic acid, Crodacid, E570, Edenor, Emersol, Hystrene, Industrene, Kortacid 1895, 
Pearl Steric, Pristerene, stereophonic acid, Tegostearic. 
Chemical Name and CAS Registry Number 
 Octadecanoic acid [57-11-4] 
Functional Category 
 Emulsifying agent, Solubilizing agent, Tablet and Capsule lubricant. 
Applications in Pharmaceutical Formulation 
 Stearic acid is widely used in oral and topical pharmaceutical formulations.  
It is mainly used in oral formulations as a  
• Tablet and capsule lubricant, binder, in combination with shellac as a tablet coating.  
• In topical formulations, stearic acid is used as an emulsifying and solubilizing agent in       
the preparation of creams. 
• Stearic acid is used as the hardening agent in glycerin suppositories. 
Table 7.6: Application of Stearic acid 
Use Concentration (%) 
Ointments and creams 1–20 
Tablet lubricant 1–3 
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Table 7.7: Typical Properties of Stearic Acid 
Acid 
Value 
Density (g/cm3) Melting 
Point  °C 
Moisture 
content 
Saponification 
value Bulk Tapped True 
200-212 0.537 0.571 0.980 554 No Water 200-220 
 
Solubility: Freely soluble in benzene, carbon tetrachloride, chloroform, and ether, soluble in    
ethanol (95%), hexane and propylene glycol, practically insoluble in water. 
Specific surface area: 0.51–0.53m2/g 
Stability and Storage Conditions 
 Stearic acid is a stable material, an antioxidant may also be added to it. The bulk material 
should be stored in a well-closed container in a cool, dry place. 
Incompatibilities 
• Stearic acid is incompatible with most metal hydroxides and may be incompatible with 
oxidizing agents. 
• Insoluble stearates are formed with many metals, ointment bases made with stearic acid 
may show evidence of drying out or lumpiness due to such a reaction when 
compounded with zinc or calcium salt.  
• Incompatible with naproxen, Stearic acid has been reported to cause pitting in the film 
coating of tablets coated using an aqueous film-coating technique, the pitting was found 
to be a function of  the melting point of the stearic acid. 
 
 
 
 
 
 
 
 
 
 
Excipient profile 7 
 
43 Department of Pharmaceutics, Madras Medical College 
 
CROSPOVIDONE72 
Nonproprietary Names 
BP, USPNF  : Crospovidone 
PhEur           : Crospovidonum 
Synonyms 
 Crosslinked povidone, E1202, Kollidon CL, Kollidon CL-M, Polyplasdone XL, 
Polyplasdone XL-10, polyvinylpolypyrrolidone, PVPP, 1-vinyl-2-pyrrolidinone homopolymer. 
Chemical Name and CAS Registry Number 
 1-Ethenyl-2-pyrrolidinone homopolymer [9003-39-8] 
Functional Category 
 Tablet disintegrant. 
 Applications in Pharmaceutical Formulation 
• Crospovidone is used as tablet disintegrant and dissolution agent at concentration      
2-5%  
• Crospovidone can also be used as a solubility enhancer 
Table 7.8: Typical Properties of Polyplasdone XL 
Acidity/alkalinity 
Density 
Moisture content 
Bulk Tapped 
pH 5-8 0.213 0.273 Maximum sorption 60% 
 
 
Solubility 
 Practically insoluble in water and most common organic solvents. 
Stability and storage conditions 
 Crospovidone is hygroscopic, and should be stored in cool and dry place 
Incompatibilities 
 Crospovidone is compatible with most organic and inorganic pharmaceutical ingredients. 
When exposed to a high water level, crospovidone may form molecular adducts with some 
materials. 
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COLLOIDAL SILICON DIOXIDE72 
Nonproprietary Names 
BP  : Colloidal anhydrous silica 
PhEur : Silica colloidalis anhydrica 
USPNF : Colloidal silicon dioxide 
Synonyms 
 Aerosil, Cab-O-Sil, Cab-O-Sil M-5P, colloidal silica, fumed silica, light anhydrous silicic 
acid, silicic anhydride, silicon dioxide fumed, Wacker HDK. 
 Chemical Name and CAS Registry Number 
 Silica [7631-86-9] 
Functional Category 
 Adsorbent, anticaking agent, emulsion stabilizer, glidant, suspending agent, tablet 
disintegrant, thermal stabilizer, viscosity-increasing agent. 
Applications in Pharmaceutical Formulation 
 Colloidal silicon dioxide is widely used in pharmaceuticals, cosmetics and food products. 
• To improve the flow properties of powders in a number of processes such as tableting 
• To stabilize emulsions and as a thixotropic thickening and suspending agent in gels and 
semisolid preparations.  
• In aerosols, other than those for inhalation, colloidal silicon dioxide is used to promote 
particulate suspension, eliminate hard settling, and minimize the clogging of spray 
nozzles. 
• As a tablet disintegrant and as an adsorbent dispersing agent for liquids in powders. 
• Colloidal silicon dioxide is frequently added to suppository formulations containing 
lipophilic excipients to increase viscosity, prevent sedimentation during molding, and 
decrease the release rate. 
• Colloidal silicone dioxide is also used as an adsorbent during the preparation of wax 
microspheres 
• As a thickening agent for topical preparations 
• Used to aid the freeze-drying of nanocapsules and nanosphere suspensions. 
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Table 7.9: Application of Colloidal Silicon dioxide 
Use Concentration (%) 
Aerosols 0.5–2.0 
Emulsion stabilizer 1.0–5.0 
Glidant 0.1–0.5 
Suspending and thickening agent 2.0–10.0 
 
Table 7.10: Typical Properties of Colloidal silicon dioxide 
Acidity/alkalinity 
4%w/v aq. dispersion 
Density(g/cm3) Flowablity 
  (% CI) 
Refractive index 
Bulk Tapped 
pH 3.5-4.4 0.029-0.042 0.04 35.52% 1.46 
 
Particle size distribution: 7–16 nm. 
Solubility                    : Practically insoluble in organic solvents, water, and acids, except 
hydrofluoric acid, soluble in hot solutions of alkali hydroxide, 
forms a colloidal dispersion with water. 
Specific gravity         : 2.2 
Specific surface area      : 200–400m2/g  
Stability and Storage Conditions 
 Colloidal silicon dioxide is hygroscopic. It should be stored in a well-closed container. 
Incompatibilities 
 Incompatible with diethylstilbestrol preparations. 
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ISOPROPYL ALCOHOL72 
Nonproprietary Names 
BP, USP     : Isopropyl alcohol 
JP  : Isopropanol 
PhEur : Alcohol isopropylicus 
Synonyms 
 Dimethyl carbinol, IPA, Isopropanol, Petrohol, 2-propanol, sec-propyl alcohol. 
 Chemical Name and CAS Registry Number 
 Propan-2-ol [67-63-0] 
Functional Category 
 Disinfectant, Solvent.  
Applications in Pharmaceutical Formulation 
• Isopropyl alcohol (propan-2-ol) is used in cosmetics and pharmaceutical formulations 
primarily as a solvent in topical formulations 
• It is used as a solvent both for tablet film-coating and for tablet granulation, where the 
isopropyl alcohol is subsequently removed by evaporation  
• 70% v/v aqueous solution is used as a topical disinfectant 
Typical Properties 
 Antimicrobial activity: isopropyl alcohol is bactericidal, at concentrations greater than 
70% v/v and it is a more effective antibacterial preservative than ethanol (95%). 
Auto ignition temperature   : 42.5°C 
Boiling point    : 82.4°C 
Dielectric constant    : D20 = 18.62 
Explosive limits    : 2.5–12.0% v/v in air. 
Flammability    : flammable. 
Flash point                             : 11.7°C (closed cup), 13°C (open cup). The water azeotrope has   
a flash point of 16°C. 
Freezing point              : 89.5°C 
Melting point    : 88.5°C 
Moisture content          : 0.1–13% w/w for commercial grades  
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Refractive index                    

 nD
20
 = 1.3776 

 nD
25
 = 1.3749 
Solubility    
 Miscible with benzene, chloroform, ethanol (95%), ether, glycerin, and water. Soluble in 
acetone, insoluble in salt solutions. Forms an azeotrope with water, containing 87.4% w/w 
isopropyl alcohol. 
Specific gravity  : 0.786 
Vapor density (relative) : 2.07 (air = 1) 
Vapor pressure   
o 133.3 Pa (1mmHg) at -26.1°C 
o 4.32 kPa (32.4 mmHg) at 20°C 
o 5.33 kPa (40 mmHg) at 23.8°C 
o 13.33 kPa (100 mmHg) at 39.5°C 
Viscosity (dynamic)   : 2.43 mPa s (2.43 cP) at 20°C 
Stability and Storage Conditions 
 Isopropyl alcohol should be stored in an airtight container in a cool, dry place. 
 Incompatibilities 
 Incompatible with oxidizing agents such as hydrogen peroxide and nitric acid, sodium 
chloride, sodium sulfate and other salts sodium hydroxide. 
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DISEASE PROFILE18, 74-77 
OSTEOARTHRITIS 
 Osteoarthritis (OA) represents failure of the diarthrodial (movable, synovial-lined) joint. 
It is also erroneously called as degenerative joint disease. OA is primarily a disease of cartilage 
that reflects a failure of the chondrocyte to maintain proper balance between cartilage 
formation and destruction. This leads to loss of cartilage in the joint, local inflammation, 
pathologic changes in underlying bone, and further damage to cartilage triggered by the 
affected bone. 
 According to the American College of Rheumatology, OA may be of 
  Idiopathic  
o Localized (spine, knee, hip, hands, feet, elbow, shoulder, and other joints)  
o Generalized (involving 3 or more joints)  
  Secondary  
o Trauma  
o Developmental and congenital diseases (dysplasia etc.)  
o Metabolic diseases (gout etc.)  
o Endocrine disorders (diabetes, hypothyroidism etc.)  
o Calcium deposition diseases (pyrophosphate, hydroxyapatite etc.)  
o Other bone and joint diseases (rheumatoid arthritis etc.)  
o Neuropathic (Charcot) arthropathy  
o Septic arthritis  
Epidemiology  
 OA is the most common joint disease of humans. Among the elderly, knee OA is the 
leading cause of chronic disability in developed countries. Some 100,000 people in the United 
States are unable to walk independently from bed to bathroom because of OA of the knee or 
hip. 
o In older individuals, hip OA is more common in men, while OA of interphalangeal joints 
and the thumb base is more common in women. Similarly symptomatic knee OA is more 
common in women than in men 
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o Racial differences exist in both the prevalence of OA and the pattern of joint involvement. 
The Chinese in Hong Kong have a lower incidence of hip OA than whites. OA is more 
frequent in Native Americans than in whites. Interphalangeal joint OA and especially hip 
OA are much less common in South African blacks than in whites in the same population  
o Age is the most powerful risk factor for OA. In a radiographic survey of women 45 years, 
only 2% had OA, between the ages of 45 and 64 years, however, the prevalence was 30% 
and for those 65years it was 68%. 
o The prevalence of clinician-diagnosed arthritis is estimated at 46 million in the United 
States and is projected to increase to nearly 67 million by 2030, of which 25 million are 
expected to report arthritis related activity limitations. 
Incidence 
 The overall incidence of hip or knee OA is approximately 200 per 100,000 person-years. 
Approximately one-half million symptomatic new cases of OA are estimated to occur annually 
in the United States. 
Risk Factors for OA 
  Age  
  Repetitive stress, e.g.  Vocational 
  Female sex  
  Obesity 
  Race Congenital/developmental defects 
  Genetic factors Prior inflammatory joint disease 
  Major joint trauma 
  Metabolic/endocrine disorders 
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Developmental Stages of Osteoarthritis 
1. Destruction of the cartilage 
 Proteolytic damage to the cartilage matrix 
2. Inflammation of the synovial membrane 
 Fibrillation and erosion of the cartilage surface and release of degradation 
products from the synovial fluid 
3. Remodeling of subchondral bone 
 The synovial cells consume the degradation products. Production of 
inflammatory proteases and cytokines. 
Physiopathology of Osteoarthritis  
 The physiopathology of OA is not completely understood, but progress is being made.  
• Under normal conditions, the components of the cartilage matrix are gradually 
replaced. Chondrocytes are the cells responsible for this metabolism, in which 
synthesis (anabolism) and destruction (catabolism) are balanced in a coordinated way 
• When this process is altered, a series of changes occurs in the morphological and 
biomechanical characteristics of cartilage that make it fail to perform its function.  
• Protease inhibitors and anti-inflammatory cytokines participate in the anabolic 
process, where the final aims are the formation of the extracellular matrix and cell 
proliferation.  
• Pro-inflammatory cytokines and proteases participate in the catabolic process, which 
results in the destruction of the cartilage matrix and a reduction of cell proliferation. 
Signs and Symptoms 
 Nearly all patients have pain in the affected joints, with the hands, knees, and hips being 
the most common locations with motion, but pain in late disease can occur with rest. 
• Joint stiffness resolves with motion; recurs with rest 
• Joint stiffness with or without joint enlargement 
• Crepitus, a crackling or grating sound heard with joint movement that is caused by 
irregularity of joint surfaces may be present 
• Limited range of motion that may be accompanied by joint instability 
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• Late-stage disease is associated with joint deformity  
Diagnosis  
  In general, the disease can be detected because of its clinical and radiological signs. 
Some of the methods used to detect the clinical manifestations of osteoarthritis include: 
• Measuring pain using Huskisson’s Visual Analogue Scale, WOMAC (Western 
Ontario and McMaster Universities) Osteoarthritis Index  
• Measuring functional status  
• Joint-fluid aspiration  
• Radiology  
• Other tests include: Nuclear Magnetic Resonance (NMR), Ultrasound, Bone 
Gammagram, CT scan, Arthroscopy. 
• A system of Radiographic Grading of osteoarthritis is also used. It was developed by 
Kellgren and Lawrence and is key in current radiological assessment of osteoarthritis. 
Table 8.1: Grades of Osteoarthritis 
        
 
 
 
 
Grade Classification Description 
0 Normal No characteristic symptoms of osteoarthritis 
1 Doubtful Indications of Osteophytes Significance doubtful 
2 Minimal Definite Osteophytes 
3 Moderate Moderate narrowing of joint space 
4 Severe Joint space very narrow, with Subchondral-bone sclerosis 
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Treatment 
 The most common symptom associated with OA is pain, which leads to decreased 
function and motion. Pain relief is the primary objective of medication therapy 
 
Non Pharmacologic Measures 
 Non pharmacologic therapy is the foundation of the pharmaceutical care plan and should 
be initiated before or concurrently with pharmacologic therapy. 
• Reduction Of Joint Loading 
• Patellar taping 
• Thermal modalities  
• Exercise  
• Wedged insoles/orthoses 
• Diet 
Pharmacologic Therapy 
 Drug therapy for OA today is palliative, no pharmacologic agent has been shown to 
prevent, delay the progression of, or reverse the pathologic changes of OA in humans. It 
includes the following,   
• NSAID and Acetaminophen 
• Glucocorticoid injection 
• Intraarticular Injection Of Hyaluronan 
• Opioids 
• Rubefacients/Capsaicin 
• Orthopedic surgery 
• Glucosamine, Chondroitin Sulfate 
• Cartilage regeneration 
 
 Recommended drug treatment starts with acetaminophen ≤4 g/day and topical analgesics 
as needed. If acetaminophen is ineffective, NSAIDs may be used, often providing satisfactory 
relief of pain and stiffness. 
 
Disease Profile 8 
 
54 Department of Pharmaceutics, Madras Medical College 
 
RHEUMATOID ARTHRITIS  
 Rheumatoid arthritis (RA) is a chronic multisystem disease of unknown cause. The 
characteristic feature of RA is persistent inflammatory synovitis, usually involving peripheral 
joints in a symmetric distribution.  
 The potential of the synovial inflammation to cause cartilage damage and bone erosions 
and subsequent changes in joint integrity is the hallmark of the disease. 
Epidemiology 
• The prevalence of RA is approximately 0.8% of the population. 
• The disease is three times more common in women. In people ages 15 to 45 years, 
women predominate by a ratio of 6:1. The sex ratio is approximately equal among 
patients in the first decade of life and in those older than age 60 years 
• Rheumatoid arthritis is six times more common among dizygotic twins and non-twin 
children of parents with rheumatoid factor-positive erosive rheumatoid arthritis when 
compared with children whose parents do not have the disease 
• If one of a pair of monozygotic twins is affected, the other twin has a 30 times greater 
risk of developing the disease. 
Etiology 
 The cause of RA remains unknown. It has been suggested that RA might be a 
manifestation of the response to an infectious agent in a genetically susceptible host. The 
factors that initiate the inflammatory process are unknown. 
• Chronic inflammation of the synovial tissue lining the joint capsule results in the 
proliferation of this tissue. The inflamed, proliferating synovium characteristic of 
rheumatoid arthritis is called Pannus.  
• This Pannus invades the cartilage and eventually the bone surface, producing erosions of 
bone and cartilage and leading to destruction of the joint.  
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Pathophysiology 
 In rheumatoid arthritis, this no longer can differentiate self from non-self tissues and 
attacks the synovial tissue and other connective tissues. Most patients with rheumatoid arthritis 
form antibodies called Rheumatoid Factors. 
• Rheumatoid factors have not been identified as pathogenic, nor does the quantity of 
these circulating antibodies always correlate with disease activity. 
• Seropositive patients tend to have a more aggressive course of their illness than do 
seronegative patients. 
• Immunoglobulins can activate the complement system and other inflammatory 
mediators such as T-cells (helper and killer),TNF, IL-1, IL-6, IL-4,IL-5, IL-10 results 
in activation of cytokines which are directly toxic to tissues, and cytokines, which 
stimulate further activation of inflammatory processes. 
            The end results of the chronic inflammatory changes are variable. Loss of cartilage may 
result in a loss of the joint space. The formation of chronic granulation or scar tissue can lead 
to loss of joint motion or bony fusion called Ankylosis. Laxity of tendon structures can result 
in a loss of support to the affected joint, leading to instability or subluxation. Tendon 
contractures also may occur, leading to chronic deformity. 
Clinical Presentation of Rheumatoid Arthritis 
Symptoms 
• Joint pain and stiffness of more than 6 weeks’ duration 
• May also experience fatigue, weakness, low-grade fever, loss of appetite 
• Muscle pain and afternoon fatigue may also be present. 
• Joint deformity is generally seen late in the disease 
• Morning stiffness of greater than 1hr duration is an almost invariable feature of 
inflammatory arthritis and may serve to distinguish it from various Noninflammatory 
joint disorder. 
Signs 
  Tenderness with warmth and swelling over affected joints usually involving hands and 
feet. Distribution of joint involvement is frequently symmetrical. Rheumatoid nodules may 
also be present. 
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Extraarticular Manifestations 
    RA is a systemic disease with a variety of extraarticular manifestations occurs due to 
rheumatic factors 
• Rheumatoid Nodules 
• Vasculitis 
• Pulmonary Complications 
• Ocular Manifestations 
• Cardiac Involvement 
• Felty’s Syndrome 
• Osteoporosis secondary to rheumatoid involvement 
Seronegative Inflammatory Arthritis 
 Although rheumatoid arthritis may have a negative rheumatoid factor titer, a number of 
other systemic inflammatory arthritic conditions exist including psoriatic arthritis, ankylosing 
spondylitis, and arthritis associated with inflammatory bowel disease. These conditions often 
tend to be less aggressive than what is typically seen with rheumatoid arthritis. 
Diagnosis 
• No tests are specific for diagnosing RA.  
• Rheumatoid factor (RF) detectable in 60% to 70%. 
• Anticyclic citrullinated peptide (anti-CCP) antibodies have similar sensitivity to RF 
(50% to 85%) but are more specific(90% to 95%) and are present earlier in the disease. 
• Elevated erythrocyte sedimentation rate and C-reactive protein are markers for 
inflammation. 
• Normocytic normochromic anemia is common as is thrombocytosis 
• Synovial fluid analysis (Joint fluid aspiration) confirms the presence of inflammatory 
arthritis. The fluid is usually turbid, with reduced viscosity, increased protein content, 
and a slightly decreased or normal glucose concentration with  2000/µL with more than 
75% polymorphonuclear leukocytes. 
• Radiographic evaluation( Joint radiography) used to determine the  extent of cartilage 
destruction and bone erosion produced by the disease. 
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• 
99mTc Bisphosphonate bone scanning and magnetic resonance imaging, may be 
capableof detecting early inflammatory changes. 
Treatment 
 Treatment of rheumatoid arthritis is a multifaceted approach that includes pharmacologic 
and Nonpharmacologic therapies. It is aimed at relieving pain and inflammation and 
maintaining and preserving joint function. 
Non Pharmacologic Therapy 
• Rest 
• Occupational therapy 
• Physical therapy 
• Use of assistive devices 
• Weight reduction 
• Surgery 
• Tenosynovectomy, tendon repair, and joint replacements are surgical options for patients 
with RA, such management is reserved for patients with severe disease. 
Pharmacologic Therapy  
• Nonsteroidal Antiinflammatory Drugs as a result of the capacity of these  agents to 
block the activity of the COX enzymes  and therefore the production of prostaglandins, 
prostacyclin, and thromboxanes, they have analgesic, anti-inflammatory, and antipyretic 
properties 
• A disease-modifying antirheumatic drug (DMARD) include Methotrexate, 
Hydroxychloroquine, Sulfasalazine, and Leflunomide and  biologic agents that have 
disease-modifying activity include the anti-TNF drugs (Etanercept,    Infliximab, 
Adalimumab), the IL-1 receptor antagonist Anakinra, the costimulation modulator 
Abatacept, and Rituximab, which depletes peripheral B cells. 
• Less frequently used DMRDS are D-Penicillamine, gold (including  Auranofin), 
Minocycline 
• Glucocorticoid Therapy Low-dose  Prednisone (7.5 mg/dl) 
• Immunosuppressive Therapy with Azathioprine, Leflunomide, Cyclosporine, and 
Cyclophosphamide.        
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MATERIALS AND METHODS 
Table 9.1: List of materials and their applications in formulation 
S.No Name of the material 
Manufacture/ 
Supplier 
Use in formulation 
1 Aceclofenac Schwitz biotech 
Active 
Ingredient 
2 Misoprostol Fagron GmbH & Co 
Active 
Ingredient 
3 HPMC K4M Dow Colorcon 
Hydrophilic 
polymer 
4 HPMC K100M CR Dow Colorcon 
Hydrophilic 
polymer 
5 HPMC K100 LV CR Dow Colorcon 
Hydrophilic 
polymer 
6 HPMC E50 Dow Colorcon 
Hydrophilic 
polymer 
7 HPMC K15 M CR Dow Colorcon 
Hydrophilic 
polymer 
8 
Microcrystalline Cellulose 
(Ceolus KG 1000) 
Asahi Kasei, Japan Diluent 
9 
Microcrystalline cellulose 
(Vivapur Type 102) 
JRS Pharma Diluent 
10 Stearic acid Cognis, Germany Lubricant 
11 Crospovidone ISP Technologies Disintegrant 
12 
Colloidal Silicon Dioxide 
(Cabosil) 
Cabot Sanmar Glidant 
13 Isopropyl alcohol Rankem Solvent 
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Table 9.2: List of Instruments/Equipments used 
S.No Instruments/Equipments Manufacturer 
1 Mixer with Sigma blade Lumix® food processor 
2 ASTM Sieve No. 40 (425µm) Electro Pharma 
3 ASTM Sieve No. 30 (600µm) Electro Pharma 
4 ASTM Sieve No. 60 (250µm) Electro Pharma 
4 Moisture Analyzer OHAUS MB 45 
5 Tap density tester USP I Electrolab ETD-1020 
6 Friabilator USP Electrolab EF-1W 
7 Analytical balance OHAUS adventurer 
8 Top loading balance 
Essae Teraoka Limited                       
(Model DS 450cw) 
9 Disintegration Apparatus Electrolab ED-2L 
10 Dissolution apparatus Electrolab India 
10 
16 station single Rotary           
compression machine 
Cadmach, Ahmedabad, India 
11 Hardness tester 
Dr.Schleuniger Pharmatron model 
5Y tablet tester 
12 Vernier caliper Mitutoyo 
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METHODOLOGY 
PREFORMULATION STUDIES 5 
  Preformulation studies is the first step in the rational development of dosage 
forms of a drug substance, It can be defined as an investigation of physical and chemical 
properties of a drug substance alone and when combined with excipients. The overall 
objective of preformulation studies is to generate information useful to the formulator in 
developing stable and bioavailable dosage forms that can be mass produced. 
 
Drug-Excipient Compatibility Study  
  The drug and the excipients chosen for the formulation were screened for 
compatibility by physical and assay methods. 
 
Physical Compatibility Study 15 
 
 The physical compatibility studies were conducted to provide valuable 
information in selecting the appropriate excipients for the formulation. It was done by 
mixing the drugs and the excipients, taken in 2 ml glass vial and kept at 40±2⁰C/75±5% 
RH. Any change in colour of the physical mixture was observed visually. 
 
Compatibility Study by Assay and Water Content  
  Assay and Water by KF can be used to investigate the Drug-excipient 
interactions.  
 
PREPARATION OF BUFFER SOLUTIONS    
Preparation of 0.1N Hydrochloric Acid (1.2pH) 70 
 8.5 ml of the hydrochloric acid was taken and dissolved in water and made 
upto 1000 ml to get 0.1N hydrochloric acid. 
 
Preparation of  Phosphate buffer solution (6.8pH) 70 
 50 ml of 0.02 M Potassium dihydrogen phosphate was taken in a 200 ml 
volumetric flask. 22.4 ml of 0.02 M sodium hydroxide solution was added and the volume 
was made up to 200 ml using distilled water. 
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 Preparation of 1% sodium lauryl sulphate 45 
 1 g of sodium lauryl sulphate was dissolved in 100 ml of distilled water. 
 
STANDARD PLOT FOR ACECLOFENAC  
Standard plot in 0.1 N Hydrochloric Acid Buffer pH 1.2 30 
 100 mg of Aceclofenac was weighed and dissolved in 10ml of methanol and 
made up to 100 ml with 0.1 N Hydrochloric Acid buffer pH 1.2 to get a concentration of 
1mg/ml. From the stock solution 10ml was taken and diluted to 100 ml to get a 
concentration of 100 mcg/ml. The above solution was further diluted with 0.1N 
Hydrochloric acid buffer pH 1.2 to get a concentration of 2, 4, 6, 8 and 10 mcg/ml. The 
absorbance of the resulting solutions was measured at 275 nm using UV-Visible 
spectrophotometer taking 0.1 N HCl as blank. 
 
Standard plot in Phosphate Buffer pH 6.8 30 
  100 mg of Aceclofenac was weighed and dissolved in 10 ml of methanol and 
made up to 100 ml with phosphate buffer pH 6.8 to get a concentration of 1mg/ml. From 
the stock solution 10 ml was taken and diluted to 100 ml to get a concentration of 
100mcg/ml. The above solution was further diluted with phosphate buffer pH 6.8 to get a 
concentration of 2, 4, 6, 8 and 10 mcg/ml. The absorbance of the resulting solutions was 
measured at 275 nm using UV-Visible spectrophotometer taking pH 6.8 phosphate buffer 
as blank. 
 
PRECOMPRESSION STUDIES OF DRUG AND BLEND 
 
Flow Property Measurements 5  
  The flow properties of powders are critical for an efficient tabletting operation.        
A good flow of the powder or granulation to be compressed is necessary to assure efficient 
mixing and acceptable weight uniformity for the compressed tablets. The flow property 
measurements include Bulk Density, Tapped Density, Compressibility index, Hausner’s 
ratio and Angle of Repose. The flow property measurements of drug and blend were 
determined to select the type of granulation technique to be carried out for the formulation. 
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a) Bulk Density (ρb) 78 
  
 It is the ratio of total mass of powder to the bulk volume of powder. It was 
measured by pouring the weighed powder into a measuring cylinder and initial weight was 
noted. This initial volume is called the bulk volume. From this the bulk density was 
calculated according to the formula mentioned below. It is expressed in g/ml and is given 
by 
ρb = M/ Vb 
Where, M and Vb are mass of powder and bulk volume of the powder respectively. 
 
b) Tapped Density (ρt) 78 
  It is the ratio of weight of the powder to the tapped volume of powder. The 
powder was introduced into a measuring cylinder with the aid of funnel and tapped for 500 
times using Tap Density tester USP I and the volume attained is the tapped volume. It is 
expressed in g/ml and is given by 
ρt = M / Vt 
Where, M and Vt are mass of powder and tapped volume of the powder respectively. 
 
c)  Angle of Repose (θ) 78 
  The flow properties were characterized in terms of angle of repose, Carr’s 
index and Hausner’s ratio. For determination of angle of repose (θ), the drug and the blend 
were poured through the walls of a funnel, which was fixed at a position such that its lower 
tip was at a height of exactly 2.0 cm above hard surface. The drug and the blends were 
poured till the time when upper tip of the pile surface touched the lower tip of the funnel. 
Angle of repose was calculated using following equation. 
θ = tan-1(h/r) 
Where, h = height of pile in cm, r = radius of pile in cm. 
 
d) Carr’s Index (or) % Compressibility 78 
  It indicates powder flow properties. It is measured for determining the relative 
importance of interparticulate interactions. It is expressed in percentage and is given by 
CI = ρt –ρb   X 100 
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 ρt 
Where, ρt and ρb are tapped density and bulk density respectively. 
e) Hausner’s Ratio 78 
  
 Hausner’s ratio is an indirect index of ease of powder flow. It is calculated by 
the following formula. 
HR = ρt / ρb 
Where, ρt and ρb are tapped density and bulk density respectively. 
Table 9.3: Scale of flowability79 
Flow property Angle of Repose(θ) Compressibility Index (%) Hausner’s Ratio 
Excellent 25-30 <10 1.00-1.11 
Good 31-35 11-15 1.12-1.18 
Fair 36-40 16-20 1.19-1.25 
Passable 41-45 21-25 1.26-1.34 
Poor 46-55 26-31 1.35-1.45 
Very poor 56-65 32-37 1.46-1.59 
Very Very poor >65 >38 >1.60 
 
f)    Water determination by Karl Fischer Titration79 
  Four tablets were powdered in a mortar and it was taken as analyte. The Karl 
Fischer reagent was added from automated burette and the endpoint was determined 
electrometrically. At the endpoint of the titration a slight excess of the reagent cause the 
flow of current which was measured in microamperes. 
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FORMULATION DEVELOPMENT 
FORMULATION OF IMMEDIATE RELEASE BLEND OF MISOPROSTOL  
  The immediate release tablets of Misoprostol were prepared by direct 
compression technique.47 Crospovidone was used as the superdisintegrant (2%, 3% and 4% 
concentrations). The blends were compressed by 16 station tablet compression machine 
using 6.25mm round concave punches. 
           Table10.1: Composition of Immediate Release Blend 
S.No Ingredients 
mg/ tablet 
M 1 M 2 M 3 
1 Misoprostol 20 20 20 
2 Microcrystalline cellulose 100.75 99.50 98.25 
3 Crospovidone  2.5 3.75 5.00 
4 Colloidal silicon dioxide 0.5 0.5 0.5 
5 Stearic acid 1.25 1.25 1.25 
Total 125.00 125.00 125.00 
 
The immediate release tablet of Misoprostol was formulated and optimized. The 
optimized formulation was used for the final filling in the capsule. 
 
 
 
 
 
 
 
Formulation Development  10 
 
65 Department of Pharmaceutics, Madras Medical College 
 
Flowchart for formulation of Misoprostol immediate release (IR) tablets 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Misoprostol 
Microcrystalline cellulose 
(Vivapur PH 102) 
Crospovidone 
Dispensing 
Sifting(#40ASTM) 
Precompression 
study 
 Mix with Crospovidone    
Sieve Colloidal silicon dioxide and 
Stearic acid (#60 ASTM)  
 
Mixing 
Compression 
Immediate Release Tablets of 
Misoprostol 
Postcompression 
study 
Blending (Polybag) 
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FORMULATION OF ACECLOFENAC EXTENDED RELEASE TABLET 
 The extended release granules were prepared by Non aqueous wet granulation 
technique. Different grades of hydrophilic polymer HPMC such as HPMC E50, HPMC 
K100LV CR, HPMC K4M CR, HPMC K15M CR and HPMC K100M CR were used in 
different ratios. The tablets were compressed by 16 station compression machine using      
17 X 4.5mm caplet punch tooling. The optimized batch of extended release tablets were 
finally filled in the capsule along with the optimized batch of Misoprostol. 
Table 10.2: Composition of Aceclofenac Extended Release Tablets 
S.No Ingredients 
mg / tab 
A1 A2 A3 A4 A5 A6 A7 A8 
Intra granular Part (330 mg) 
1 Aceclofenac 200 200 200 200 200 200 200 200 
2 HPMC E 50 130 - - - - 65 50 40 
3 
HPMC 
K100LV CR 
- 130 - - - 65 80 90 
4 
HPMC K4M 
CR 
- - 130 - - - - - 
5 
HPMC 
K15M CR 
- - - 130 - - - - 
6 
HPMC K100 
M CR 
- - - - 130 - - - 
7 IPA q.s q.s q.s q.s q.s q.s q.s q.s 
Extra granular Part (70 mg) 
1 
MCC(Ceolus 
KG 1000) 
62 62 62 62 62 62 62 62 
2 Stearic acid  8 8 8 8 8 8 8 8 
Total weight 
(mg/tab) 
400.00 400.00 400.00 400.00 400.00 400.00 400.00 400.00 
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Flowchart for formulation of Aceclofenac Extended Release Tablets 
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Flowchart for final Tablet in capsule formulation 
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Sealing of Capsule 
Capsule containing final 
IR and ER tablets 
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POST COMPRESSION STUDIES 
1. PHYSICAL PARAMETERS 
a) General appearance 
   The general appearance of the tablets from each formulation batch was 
observed. The general appearance parameters are shape, colour, presence or absence of 
odour and taste were evaluated visually. 
 
b) Uniformity of Weight 70 
                     Twenty tablets were selected at a random and weighed individually. The 
average weight was calculated. The percentage deviation of tablets was calculated and 
compared with the standard specifications. 
Table 10.3: Uniformity of Weight70 
S.No Average weight of a tablets % Deviation 
1 80 mg or less ±10 
2 80-250 mg  ±7.5 
3 More than 250 mg ±5 
 
c) Thickness 30 
                    The thickness was measured to determine the uniformity of size and shape. 
Thickness of the tablets was measured using vernier caliper. 
 
d) Hardness 70 
                    Hardness is defined as the force required for breaking a tablet at diametric 
compression test and it is termed as tablet crushing strength. Hardness of the prepared 
formulations was determined using Dr. Schleuniger Pharmatron model 5Y tablet tester. It 
was expressed in kp. 
 
e) Friability 70 
                    Friability of the prepared formulations was determined by using Roche 
friabiltor. Pre- weighed sample of tablets was placed in the friability tester, which was then 
operated for 25 revolutions for 4 min, tablets were dedusted and reweighed. The friability 
of the tablets was calculated using the formula mentioned below. 
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% Friability =   Initial weight of the tablets – Final weight of the tablets X 100  
Initial weight of the tablets 
 
 
2. DRUG CONTENT 
 MISOPROSTOL 70 
 Instrumentation 
 A liquid chromatography consisting of an isocratic pump, a fixed volume 
injector loop UV-Visible Spectrophotometer detector and data management software. 
Chromatographic Conditions 
• Column                       : Stainless steel column 25 X 4.6 mm 
• Column packing         :  Endcapped ODS bonded to porous silica                                                                                                   
• Column temperature : 40° C 
• Flow rate                     : 0.75 ml/min 
•  Wave length               : 200nm 
• Injection volume        : 10µl 
 Reference Solution  
                 0.2 % w/v solution of Misoprostol RS in acetonitrile.  
Mobile Phase 
               Mixture of 45 volumes of acetonitrile, 55 volumes of water and 0.05 volume 
of 2.45 % w/v solution of orthophosphoric acid.  
Preparation of Test Solution 
  Twenty tablets were selected randomly and ground. The equivalent of 10 mg 
of Misoprostol was weighed and dissolved in 5 ml of acetonitrile.  
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Procedure 
•  Standard solution and test solution were filtered through 0.45 µ 
membranes filter. 
• The standard solution in five replicate and test solution in duplicate were 
injected into the chromatograph. 
• Content of  the Misoprostol as mg/ tablet was calculated using the formula 
                               Ct  =  Cs (rt /rs )                                                                                                                              
Aceclofenac 49                                                                              
  Three tablets were crushed and powder containing 200 mg of Aceclofenac was 
dissolved in 100 ml of methanol. The solution was passed through a whatman (No. 1) filter 
and analyzed by UV Visible Spectrophotometer at 275 nm after sufficient dilution with 
suitable medium (0.1N HCl and pH 6.8 Phosphate buffer).  
3. IN VITRO DISINTEGRATION STUDIES FOR IR TABLETS 5 
  The disintegration time was determined using disintegration test apparatus. 
The tablets were placed in each of the six tubes of the basket. The assembly was suspended 
in water maintained at a temperature of 37⁰C ± 2⁰C and the apparatus was switched on. The 
time taken to disintegrate the tablets completely was noted. 
4. IN VITRO DISSOLUTION STUDIES 
     Misoprostol Tablets 36 
 The release of Misoprostol was determined using USP Type II paddle 
dissolution apparatus under sink condition. 500ml of de-aerated water was used as 
dissolution medium at a temperature of 37⁰C ±0.5⁰C.  The paddle was stirred at a speed of 
50 rpm. The release studies were carried out for 30 min. 10 ml of sample was withdrawn at 
regular intervals of 10 min and the percentage of drug dissolved were determined using 
HPLC method.  
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Chromatographic conditions 
• Column : ODS 1 column of dimensions 100 X 4.6mm  
• Column temperature: 40° C 
• Flow rate : 0.75 ml/min  
• Injection volume: 500µl 
• Wavelength: 200nm  
Mobile Phase  
         The mobile phase is a mixture of acetonitrile, purified water and 24.5 g/l 
solution of orthophosphoric acid in the ratio of 55 : 45 : 0.05 v/v/v respectively. 
Standard Solution 
                       0.4 µg/ml solution of Misoprostol prepared using mobile phase and 
subsequently diluted to appropriate concentration with dissolution medium.  
Procedure 
                     The standard and sample solutions were filtered using whatman filter No.1 
and injected into the chromatograph for the determination of percentage drug release at 
different time points. 
Aceclofenac tablets 45 
    The dissolution rate of Aceclofenac ER tablets prepared were studied using 
USP type II dissolution  test apparatus employing paddle stirrer, using 0.1N hydrochloric 
acid for first 2 hours and phosphate buffer  pH 6.8 further  as dissolution fluids. In each test 
one tablet, a speed 100 rpm rotations and a temperature of 37°C ± 1°C were employed. A 
10 ml aliquot of dissolution medium was withdrawn at different time interval suitable 
diluted and assayed by UV Visible spectrophotometer at 275 nm. The percentage of drug 
dissolved at various time intervals 2, 4, 6, 8, 10, 12 hrs was calculated and plotted against 
time. 
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5. EVALUATION OF IN VITRO RELEASE KINETICS 51 
                     To study the in vitro release kinetics of the ER tablets, data obtained from the   
in vitro dissolution study of optimized formulation were plotted in various kinetic models.   
Zero order equation  
            The zero order release kinetics can be obtained by plotting cumulative % drug 
released Vs time (hours). It is ideal for the formulation to have release profile of zero order 
to achieve pharmacological prolonged action. 
C = K0t 
Where,  K0 = Zero order constant in conc. / time 
               t = Time in hours 
 
First order equation  
            The graph was plotted as log % cumulative drug remaining Vs time in hours. 
Log C = logC0 – Kt/2.303 
C0 = Initial drug concentration 
K = First order constant 
  t = Time in hours.    
 
Higuchi kinetics 
                      The graph was plotted with % cumulative drug released Vs square root of 
time. 
Q = Kt1/2 
K = Constant reflecting design variable system (Differential rate constant) 
t = Time in hours. 
The drug release rate is inversely proportional to the square root of time. 
Hixson and Crowell erosion equation 
                       To evaluate the drug release with changes in the surface area and the 
diameter of particles, the data were plotted using the Hixson and Crowell erosion equation. 
The graph was plotted by cube root of % drug remaining Vs Time in hours. 
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Q01/3 – Qt1/3 = KHC t 
 
Qt = Amount of drug released at time t 
Q0 = Initial amount of drug 
KHC = Rate constant for Hixson Crowell equation 
 
Korsmeyer – Peppas equation 
                     To evaluate the mechanism of drug release, it was further plotted in Peppas 
equation as log cumulative % of drug released Vs log time. 
Mt/Mα = Ktn 
 
 Where,  Mt/Mα = Fraction of drug released at time t 
                  t = Release time  
                  K = Kinetics constant (Incorporating structural and geometric characteristics of 
the formulation)  
                   n = Diffusional exponent indicative of the mechanism of drug release. 
Table 10.3: Evaluation of in vitro release kinetics51 
Zero-order reaction % Cum. drug release Time (hours) 
First order reaction Log % cum. drug remaining Time in hours 
Higuchi kinetics % cum. drug release Square root of time 
Korsmeyer-Peppas 
equation 
Log cum.% of drug release Log time 
Hixon and crowell 
erosion equation 
Cube root of % drug remaining Time in hours 
  
 The n value obtained is used to characterize different release mechanisms for 
cylindrical shaped matrices.51 
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Table 10.4: Diffusion exponent and its mechanism 
Diffusion exponent (n) Overall solute diffusion mechanism 
0.45 Fickian diffusion 
0.45 < n < 0.89 Anomalous (non-Fickian) diffusion 
0.89 Case-II transport 
n > 0.89 Super case-II transport 
 
 
6. STABILITY STUDY 49 
                    Stability study of optimized formulation of tablet in capsule was carried out 
according to ICH guidelines. Accelerated stability study of encapsulated formulation can be 
performed by packing 30 units of capsules in 60cc HDPE Bottle and 33mm PP Child 
Resistant closure with induction seal liner and 1 g per bottle of 6 g/yard Cotton as dunnage. 
Then these bottles are kept at and 40°C ±2ºC/75±5% RH. The samples were withdrawn at 
1st, 2nd and 3rd month and analyzed for the following raiders, 
• Thickness 
• Assay  
• Disintegration for IR tablets only 
• Dissolution  
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RESULTS AND DISCUSSION 
           The present investigation was to formulate tablets for immediate release of 
Misoprostol and extended release of Aceclofenac enclosed in a capsule for pain 
management with GI protection. The drug-excipient study was conducted to reveal the 
excipient compatibility with the drug. The physical and chemical compatibility of drug 
and excipients are given in Table 11.1 and 11.2. 
PREFORMUALTION STUIDES 
Drug -Excipient Compatibility Study 
Table 11.1:  Drug– Excipient Compatibility 
    S.No Drug-Excipient Ratio Initial Appearance 
Assay % WC 
1 MI-MCC Type 102 1:1 97.29 4.75 White powder 
2 MI-Crospovidone 1:0.25 98.90 3.81 White powder 
3 MI-Cabosil 1:0.25 96.58 2.79 White powder 
4 MI-Stearic acid 1:0.25 98.05 1.25 White to off white powder 
5 AC-MCC KG 1000 1:0.5 98.05 4.32 White powder 
6 AC -HPMC E50 1:0.5 96.07 3.12 White powder 
7 AC-Stearic acid 1:0.25 99.30 0.10 White to off white powder 
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Table 11.2: Drug– Excipient Compatibility (Accelerated Stability Studies) 
S.No Drug-excipient 
40± 2° C/75±5% RH-2W 40± 2° C/75±5% RH-4W 
Assay% WC Appearance Assay% WC Appearance 
1 MI-MCC PH 102 93.0 3.90 NC 96.0 4.62 NC 
2 MI-Stearic Acid 95.0 0.81 NC 93.0 1.14 NC 
3 MI-Colloidal 
silicon dioxide 
94.0 2.43 NC 94.0 2.56 NC 
4 MI-Crospovidone 91.0 3.68 NC 97.0 3.77 NC 
5 AC-MCC KG 1000 95.0 3.75 NC 95.7 4.21 NC 
6 AC-HPMC E50 96.08 2.78 NC 94.03 3.00 NC 
7 AC-Stearic acid 97.0 0.05 NC 95.0 0.07 NC 
 
NC- No change,  WC- Water content, MI- Misoprostol, AC- Aceclofenac 
    Inference 
                The excipients were found to be compatible with the drug.  
 
STANDARD PLOT FOR ACECLOFENAC 
 The concentration and absorbance for Aceclofenac in 0.1N HCl (pH 1.2) and 
Phosphate buffer (pH 6.8) at wavelength 275 nm was measured using UV Visible 
Spectrophotometer. The results are given in Table 11.3. 
Table 11.3: Standard plot for Aceclofenac 
S. No 
Concentration 
(mcg/ml) 
Absorbance at λ275nm 
pH 1.2 pH 6.8 
1 0 0 0 
2 2 0.024 0.061 
3 4 0.049 0.122 
4 6 0.074 0.187 
5 8 0.097 0.243 
6 10 0.125 0.302 
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                                   Fig 11.1: Standard plot of Aceclofenac in pH 1.2 
 
 
 
Fig 11.2: Standard plot of Aceclofenac in pH 6.8 Phosphate Buffer 
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EVALUATION OF IR FORMULATION 
PRECOMPRESSION STUDY 
The drug and the formulated blends were evaluated for precompression parameters. The 
results are given in Table 11.4. 
Table 11.4: Precompression study of drug and formulated blends 
Drug and 
Formulation 
Bulk 
Density 
g/cm3 * 
Tapped 
Density 
g/cm3 * 
Compressibility 
index (%)* 
Hausner’s 
Ratio* 
Angle of 
Repose 
(Degree) 
MI 
05848±  
0.0091 
0.6754 ± 
0.0072 
13.42 ±   
0.4430 
1.15 ±  
0.0072 
21.50 
M1 
0.4987±  
0.0078 
0.5361 ± 
0.0056 
8.52 ± 
1.02 
1.09 ± 
0.01 
22.36 
M2 
0.5018± 
0.0021 
0.5590 ± 
0.018 
10.24 ± 
1.75 
1.11 ± 
0.0220 
23.45 
M3 
0.4863± 
0.0143 
0.5317 ± 
0.0025 
8.53 ± 
2.62 
1.09 ± 
0.0280 
23.05 
* Mean ± S.D (n = 3) 
                  The bulk density of the IR blends ranged from 0.4863 to 0.5018 g/cm3 and the 
tapped density ranged from 0.5317 to 0.5590 g/cm3. The compressibility index of the IR 
blends ranged from 8.52% to 10.24% and Hausner’s ratio ranged from 1.09 to 1.11.The 
angle of repose of the IR blends ranged from 22.36 to 23.45. The formulated blend shows 
good flow property so direct compression was employed.70 The IR blends were evaluated 
for bulk density, tapped density, compressibility index, Hausner’s ratio and Angle of 
Repose.79 
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POST COMPRESSION STUDY FOR TABLETS 
UNIFORMITY OF WEIGHT 
              The uniformity of weight of the formulated tablets is given in Table 11.5 
Table 11.5: Uniformity of weight of the formulated tablets 
Formulation Uniformity of weight (mg) * 
M1 125.28±0.3382 
M2 125.36±0.4852 
M3 125.58±0.5263  
* Mean± S.D (n=20) 
       The tablets comply with the test for uniformity of weight.70 
TABLET THICKNESS  
            The thickness of the formulated tablets is given in Table 11.6 
                                      Table 11.6: Thickness of formulated tablets  
Formulation Thickness (mm) * 
M1 3.114±0.0219 
M2 3.112±0.0109 
M3 3.114±0.0308 
* Mean± S.D (n=5) 
The tablets possess uniform thickness. 
HARDNESS 
The hardness of the formulated tablets is given in Table 11.7 
Table 11.7: Hardness of formulated tablets 
Formulation Hardness (kp) * 
M1 5.16±0.0547 
M2 5.18±0.0457 
M3 5.17±0.0358 
* Mean± S.D (n=5) 
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All the formulated tablets showed sufficient mechanical strength to resist the 
transportation and handling. 
 FRIABILITY  
The friability of the formulated tablets are given in Table 11.8. 
Table 11.8: Friability of formulated tablets 
Formulation % Friability  
M1 0.34 
M2 0.42 
M3 0.40 
         
 The percentage friability of all the formulations was within the acceptable limits.70 
DRUG CONTENT 
The drug content of the IR tablets is given in the Table 11.9.  
Table 11.9: Drug content of formulated IR tablets 
Formulation % Drug Content 
M1 98.76 ± 0.1300 
M2 97.48 ± 0.0100  
M3 98.56± 0.1201 
                           
 Fig 11.3: Drug content of IR tablets          
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DISINTEGRATION TIME
The disintegration time of the I
Table
Formulation
M
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                                    Fig.11.4: Disintegration time of IR tablets
  The disintegration time of the IR 
the tablets disintegrated within the Pharmacopoeial limits.
IR tablets containing 4% Crospovidone 
formulated IR tablets. 
IN VITRO DISSOLUTION STUDY
                     The in vitro dissolution of immediate release formulations of 
given in the Table 11.11. 
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R tablets is given in the Table 11.10.  
11.10: Disintegration time of IR tablets 
 Disintegration time (minutes) 
1 8.50 ± 0.012 
2 4.29 ± 0.0004 
 
2.10 ± 0.0020 
 
tablets ranged from 2.10
70 The disintegration time of the 
was found to have faster disintegration among the 
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-8.50 minutes. All 
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Table11.11: In vitro Dissolution study of IR formulation of Misoprostol 
 
          
 
                                                                
 
 
 
 
                   Fig.11.5: In vitro Dissolution study of IR tablets of Misoprostol  
The formulation M3 containing 4% of Crospovidone released the drug faster when 
compared to M1 and M2 formulations. The formulation M3 released 98.94% of 
Misoprostol at the end of 30mins. Therefore formulation M3 was optimized and selected 
for filling in capsule.  
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10 20.39±0.7112 30.35±1.22 60.28±0.7 
20 48.38±0.6515 60.78±1.988 85.02±0.5178 
30 69.99±1.5076 73.49±1.817 98.94±0.4564 
40 78.42±0.7616 87.52±0.4659  
50 87.81±0.9269 98.27±0.3463  
60 96.95±0.5162 
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EVALUATION OF ER FORMULATION 
PRECOMPRESSION STUDY  
The drug and the formulated blends of ER formulation were evaluated for precompression 
parameters. 
The results are given in the Table 11.12. 
Table11.12: Precompression study of drug and formulated blends 
Drug and 
formulation 
Bulk 
density 
g/cm3 * 
Tapped 
density 
g/cm3 * 
Compressibility 
Index (%) 
Hausner’s 
Ratio 
Angle of 
Repose 
(Degree) 
AC 
0.6511± 
0.0012 
0.8326± 
0.0010 
21.79 ±      
0.0907 
1.27 ± 
0.0000 
37.99 
A1 
0.5916± 
0.0018 
0.7682± 
0.0023 
22.99 ± 
 0.5831 
1.30 ± 
0.0000 
32.45 
A2 
0.5886± 
0.002 
0.7693± 
0.0011 
23.48 ±  
0.3329 
1.30 ± 
0.0057 
33.06 
A3 
0.589± 
0.0024 
0.7711± 
0.0019 
23.62 ± 
0.4635 
1.31 ± 
0.0057 
32.12 
A4 
0.5880± 
0.0024 
0.7689± 
0.0011 
23.54 ± 
0.1563 
1.31 ± 
0.0058 
34.36 
A5 
0.5883± 
0.0025 
0.7695± 
0.0013 
23.55 ± 
0.1674 
1.30 ± 
0.0057 
31.58 
A6 
0.5898± 
0.0009 
0.7696± 
0.0006 
23.37 ± 
0.2271 
1.31 ± 
0.0058 
32.10 
A7 
0.5894± 
0.0001 
0.7708± 
0.0057 
23.52 ± 
0.7000 
1.31 ± 
0.01525 
33.42 
A8 
0.5897± 
0.0019 
0.7705± 
0.0024 
23.47 ± 
0.1053 
1.30 ± 
0.0057 
33.36 
* Mean± S.D (n=3) 
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  The bulk density of the formulated blends ranged from 0.5880 to 0.5916 and 
tapped density ranged from 0.7682 to 0.7711. The compressibility index ranged from 
22.99 to 23.62 and Hausner’s ratio ranged from 1.30 to 1.31. The Angle of repose ranged 
from 31.58 to 34.36. The formulated blends did not show adequate flow properties for 
compression.79 Hence Non aqueous wet granulation method was employed. The 
formulated ER granules were evaluated for bulk density, tapped density, compressibility 
index, Hausner’s ratio and Angle of Repose. The results are given in the Table 11.13 
Table11.13: Precompression study of Extended release granules 
Formulation 
Bulk 
density 
g/cm3 
Tapped 
density 
g/cm3 
Compressibility 
Index (%) 
Hausner’s 
Ratio 
Angle of 
Repose 
(Degree) 
A1 
0.5852± 
0.0046 
0.7316± 
0.0009 
20.0 ±  
0.6560 
1.24± 
0.0115 
25.25 
A2 
0.5889± 
0.0018 
0.7395± 
0.0008 
20.35 ± 
0.3000 
1.25 ± 
0.0057 
25.12 
A3 
0.5912± 
0.0011 
0.741± 
0.0008 
20.21 ± 
0.2402 
1.25 ± 
0.0057 
24.29 
A4 
0.5905± 
0.0056 
0.7393± 
0.0004 
20.11 ± 
0.862 
1.25 ± 
0000 
23.22 
A5 
0.5906± 
0.0005 
0.7392± 
0.0004 
20.09 ± 
0.0400 
1.25 ± 
0000 
22.78 
A6 
0.5916± 
0.0008 
0.7414± 
0.0011 
20.19 ± 
0.2371 
1.25 ± 
0.0057 
25.11 
A7 
0.5904± 
0.0003 
0.7405± 
0.0015 
20.25 ± 
 0.1404 
1.25 ± 
0.0000 
26.0 
A8 
0.5911± 
0.0006 
0.7328± 
0.0048 
19.32 ±  
0.6178 
1.23 ± 
0000 
27.26 
                   
  The bulk density of the ER granules ranged from 0.5852 to 0.5916 g/cm3 and 
the tapped density of ranged from 0.7316 to 0.7410 g/cm3. The compressibility index of 
the ER granules ranged from 19.32 to 20.35% and Hausner’s ratio ranged from 1.23 to 
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1.25. The Angle of Repose of the ER granules ranged from 22.78 to 27.26. The 
formulated granules shows good flow property.79 
POST COMPRESSION STUDY 
UNIFORMITY OF WEIGHT 
                   The uniformity of weight of the formulated tablets is given in Table11.14. 
Table 11.14: Uniformity of Weight 
Formulation Uniformity of weight (mg) * 
A1 400.33 ±0.4723 
A2 400.06±1.3848 
A3 400.35±0.5060 
A4 400.65±1.7588 
A5 400.06±0.9147 
A6 400.49±0.7427 
A7 400.49±0.8312 
A8 400.31±0.7053 
* Mean± S.D (n=20) 
The tablet complies with the test for uniformity of weight.70 
TABLET THICKNESS  
The thickness of the formulated tablets is given in table11.15 
  Table 11.15: Thickness of formulated tablets  
Formulation Thickness (mm) * 
A1 4.12±0.0001 
A2 4.11±0.0055 
A3 4.12±0.0055 
A4 4.11±0.0055 
A5 4.12±0.0084 
A6 4.12±0.0055 
A7 4.12±0.0070 
A8 4.11±0.0055 
* Mean± S.D (n=5) 
The tablets have uniform thickness. 
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HARDNESS 
The hardness of the formulated tablets is given in Table11.16. 
Table11.16: Hardness of formulated tablets  
Formulation Hardness (kp) * 
A1 6.1±0.0707 
A2 6.1±0.0894 
A3 6.12±0.8367 
A4 6.1±0.1000 
A5 6.1±0.1414 
A6 6.1±0.0707 
A7 6.1±0.0707 
A8 6.12±0.0447 
* Mean± S.D (n=5) 
All the formulated tablets showed sufficient mechanical strength to resist the 
transportation.70 
 
FRIABILITY 
The friability of the formulated tablets is given in Table 11.17.  
Table 11.17: Friability of formulated tablets  
Formulation % Friability 
A1 0.45 
A2 0.31 
A3 0.61 
A4 0.52 
A5 0.49 
A6 0.63 
A7 0.60 
A8 0.55 
 
 The percentage friability of all formulations was within the acceptable limits.70 
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DRUG CONTENT 
                     The drug content of formulated tablets are given in table 11.18. 
Table 11.18: Drug content of formulated tablets  
Formulation Drug content % 
A1 98.78 
A2 97.42 
A3 95.75 
A4 96.59 
A5 99.54 
A6 98.21 
A7 98.03 
A8 98.27 
 
All the formulations are within the acceptable limits.70  
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IN VITRO DISSOLUTION PROFILE OF ER TABLETS40 
  The in vitro dissolution study of the formulated ER tablets is given in table 11.19. 
 
Table11.19: In vitro dissolution Profile of ER tablets A1-A8 
TIME  
(HR) 
 
A1 A2 A3 A4 A5 A6 A7 A8 
0 0 0 0 0 0 0 0 0 
2 20.69± 1.6934 
13.81± 
0.7806 
27.6± 
0.4585 
23.02± 
1.0219 
26.48± 
0.5300 
7.24± 
0.5474 
11.25± 
1.3741 
9.14± 
0.1938 
4 55.52± 1.3714 
38.58± 
1.1104 
38.67± 
1.3708 
34.2± 
0.4546 
31.62± 
1.2400 
40.28± 
0.7708 
35.68± 
0.7489 
20.69± 
0.4906 
6 73.94± 0.9610 
52.4± 
1.1655 
48.96± 
0.6401 
43.52± 
0.3608 
38.48± 
0.6530 
71.17± 
1.3357 
61.02± 
0.6411 
47.97± 
0.3046 
8 88.91± 0.4220 
68.26± 
1.5928 
58.92± 
0.8882 
50.82± 
0.2344 
43.35± 
0.8411 
83.2± 
0.7530 
77.44± 
0.5079 
63.25± 
0.2541 
10 98.55± 0.5996 
92.41± 
0.7427 
61.57± 
1.0064 
57.44± 
1.0228 
44.33± 
1.0944 
94.16± 
0.9932 
86.12± 
0.3929 
85.27± 
0.2381 
12 - 98.43± 0.4062 
69.43± 
0.7155 
61.8± 
0.9528 
48.87± 
1.0953 
97.93± 
0.7219 
97.41± 
0.8251 
98.1± 
0.1890 
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Fig11.6: In Vitro Drug Release of ER Formulation A1-A4 
 
Fig11.7: In Vitro Drug Release of ER Formulation A5-A8 
  The results of in vitro dissolution study of ER tablets showed that the 
formulation A8 containing HPMC E50 40 mg and HPMC K100 LVCR 90 mg showed 
ideal release of the drug in 12 hours. Other formulations of ER not meeting the objective. 
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IN VITRO RELEASE KINETICS 
The values obtained from in vitro dissolution of Aceclofenac Extended release tablets 
were fitted to kinetic models. The results are given in table 11.18 and fig. 
 
Table 11.20: In vitro release kinetics of Aceclofenac ER tablets 
Time 
(Hr) 
% Cum 
Drug 
Release 
% Cum 
Drug 
Remaining 
Log % 
Cum  
Drug 
Remain
ing 
Square 
root of 
time 
Log 
time 
Log % 
cum  
drug 
release 
Cube root  
of  %  
drug 
remaining 
0 0 100 2 0 0 0 4.6415 
2 9.14 90.86 1.9583 1.4142 0.3010 0.9609 4.4956 
4 20.69 79.31 1.8993 2 0.6020 1.3157 4.2964 
6 47.97 52.03 1.7162 2.4494 0.7781 1.6809 3.7332 
8 63.25 36.75 1.5652 2.8284 0.9030 1.8010 3.3246 
10 85.27 14.73 1.1682 3.1622 1 1.9307 2.4513 
12 98.1 1.9 0.2787 3.4641 1.0791 1.9916 1.2385 
 
 
Determination of drug release mechanism of extended release tablets 
 
 
 
 
 
Fig 11.8: Zero order release kinetics plot 
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Fig 11.9: First order release kinetics plot 
 
 
Fig 11.10: Higuchi Release Kinetics plot 
 
 
Fig 11.11: Hixon Crowell Release Kinetics plot 
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Fig 11.12: Korsemeyer Peppas release kinetics plot 
 
 
Table11.21: R2 values of various Kinetic Models 
Kinetic Model R2 Value 
Zero order release kinetics 0.985 
First order release kinetics 0.787 
Higuchi release kinetics 0.851 
Hixon Crowell release kinetics 0.903 
Korsemeyer Peppas release kinetics 0.960 
 
  The kinetic parameters revealed that release data of optimized formula A8 
showed r2 value of 0.985 which is close to 1, indicating that release of drug follows zero 
order kinetics and the release is independent of concentration. 
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STABILITY STUDY 
           The optimized tablets were subjected to stability studies and the results are given in 
Table 11.22 to 11.25 
Stability study of physical parameters of the optimized formulations  
Table 11.22: Misoprostol 
Parameter Initial 
1st  
month 
2nd  
month 
3rd  
month 
Uniformity of weight 
(mg)* 
125.58± 
0.5263 
125.21±  
0.3796 
125.02± 
0.5225 
124.99± 
0.4083 
Thickness(mm)** 
3.114± 
0.0308 
3.11± 
0.0054 
3.11±              
   0.0054 
3.11±  
0.0044 
Disintegration Time 
(min) 
2.10± 
0.0152 
2.23± 
 0.1369 
2.18 ± 
0.1158 
2.21 ± 
0.0790 
Water content of 
finalized formulation 
4.72 5.16 5.37 5.62 
* Mean± S.D (n=20), ** Mean± S.D (n=5) 
  Table 11.23:  Aceclofenac  
Parameter Initial 
1st 
month 
2nd 
month 
3rd 
month 
Uniformity of weight (mg)* 
400.31± 
0.7053 
400.12± 
0.6462 
400.32± 
0.4348 
400.35± 
0.503 
Thickness(mm)** 
4.11± 
0.0055 
4.11± 
0.0054 
4.11± 
0.0083 
4.11± 
0.0054 
Water content of finalized 
formulation 
4.82 5.46 5.67 5.8 
* Mean± S.D (n=20), ** Mean± S.D (n=5) 
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Table 11.24: Assay and Dissolution profile of formulated Misoprostol tablets 
Time 
Interval 
Drug content (%) Cumulative % release 
At the end of 30 min 
Initial 98.56 98.94± 0.4564 
1st month 98.45         98.15± 0.3793 
2nd month 97.32          97.74 ± 0.3610 
3rd month 97.14          98.11± 0.2553 
 
Table 11.25: Assay and dissolution profile of formulated Aceclofenac tablets 
Time 
Interval 
 
Drug content 
(%) 
Cumulative % release with respect to 
Time(hr) 
2 6 12 
Initial 98.27 
9.14± 
0.1938 
47.97± 
0.3046 
98.1± 
0.1890 
1st month 97.33 9.23± 
0.3291 
48.43± 
0.646 
98.13± 
0.6241 
2nd month 96.87 
9.38± 
0.3824 
47.09± 
0.3906 
97.82± 
0.6614 
3rd month 96.54 
9.45± 
0.2714 
47.87± 
 0.319 
98.08± 
0.5035 
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SUMMARY AND CONCLUSION 
 A Tablet in Capsule device containing Aceclofenac ER tablet and Misoprostol IR 
tablet for Pain Management with Gastro protection was formulated. Rationale of combining a 
NSAID and a prostaglandin analogue was well justified and the design of drug delivery system 
was made simple by encapsulating two different tablets (Aceclofenac and Misoprostol) in 
single capsule and it offers advantage in terms of GI protection, Patient Compliance and 
Chronotherapeutics. 
• Aceclofenac extended release tablet 200mg was formulated using various grades of  
hydrophilic polymer such as HPMC E50, HPMC K100 LV CR, HPMC K4M CR and 
HPMC K15M CR as release retardant to prolong the release for 12 hr . 
•  Misoprostol Immediate release tablet 200mcg was formulated using Crospovidone as 
superdisintegrant at 2%, 3% and 4%.  
• Formulation characteristics such as precompression and postcompression studies of the 
developed formulations were carried out separately as per standard procedures. 
• The tablets were found to be within the limits with respect to uniformity of weight, 
hardness, thickness, diameter, friability and drug content. 
• In vitro dissolution studies for both the tablets were conducted separately. 
• Aceclofenac ER formulation A8 was optimized based on the ideal release upto 12 hr  
• The optimized Aceclofenac formulation followed Zero order release kinetics  
• Based on the disintegration time Misoprostol IR formulation M3 was optimized 
• The optimized formulations of Aceclofenac A8 and Misoprostol M3 were used for 
filling in size 0 elongated capsules. 
• The stability studies under accelerated conditions of 40± 2°C /75±5% RH was found to 
be satisfactory.  
 
  
 
  
 
 
 
 
 
 
 
 
 
 
                                             References 
References 13 
 
97 Department of Pharmaceutics, Madras Medical College 
 
REFERENCES 
1. Vinayak V Ranade, Mannfred A Hollinger. Drug Delivery Systems. 2nd ed.                  
Boca Raton: CRC press; 2004. p. 2.  
2. Chien Yie W (ed.). Novel drug delivery systems. 2nd ed. New York: Marcel Dekker, 
Inc;1992: p. 139. 
3. Jayesh Parmar, Manish Rane. Tablet formulation design and manufacture: oral Immediate 
release application.  Pharma Times 2009;41(4). 
4. Gilbert S Banker, Christopher T Rhodes (ed.). Modern Pharmaceutics. 4th ed.                
New York: Marcel Dekker, Inc.; 2002.  
5. Eugene F Fiese, Timothy A Hagen. Preformulation. In: Leon Lachman, Herbert A 
Lieberman, Joseph L Kanig. (eds.) The theory and practice of industrial pharmacy. 3rd ed. 
Mumbai: Varghese Publishing House; 1987.  p.171, 293-294,374. 
6. Jain NK. Pharmaceutical Product development. New Delhi: CBS Publisher and 
distributors; 2006. p. 426. 
7. Capscanada [Online]. Available from : http://www.capscanada.com/assets/technical% 
20specifications%20gelatin%20cc%20w%20lq  [Accessed 10th October 2011]    
8. Vyas SP, Roop K Khar. Controlled Drug Delivery concept and advances. New Delhi: 
Vallabh Prakashan; 2002. p. 1-9. 
9. Robinson JR. Sustained Release Drug Delivery Systems. In: Remington. The Science and 
Practice of Pharmacy.19th ed. San Francisco: Mack Publishing Company;1995. p.1081-
1082. 
10. Jayanthi B, Manna PK, Madhusudhan S, Mohanta GP, Manavalan R. Per oral extended 
release products -An overview. Journal of Applied Pharmaceutical Science 2011;1(2):50-
55. 
11. SunilKamboj. Matrix tablet an important tool for oral controlled release dosage forms. 
Pharmainfo.net [Online] Available from: www.pharmainfo.net/reviews/matrix-tablets-
important-tool-oral-controlled-release-dosage-forms [Accessed 15th  October 2011] 
12. Sandip B Tiwari, Ali R Rajabi-siahboomi. Modulation of drug release from hydrophilic 
matrices. Advancing process solutions pharmaceutical technology. 2008  
References 13 
 
98 Department of Pharmaceutics, Madras Medical College 
 
13. Nandita G Das, Sudip K Das. Controlled release of oral dosage forms. Formulation fill 
and finish. [Online] 2003. Available from: www.pharmtech.com/pharmatech/data/article 
standard/pharmtech/232003/59302/article.pdf [Accessed 18th October 2011] 
14. Ying-huan Li, Jia-bi Zhu. Modulation of combined release behaviours from a novel tablets 
in capsule system. Journal of Controlled Release 2004;95:381–389. 
15. Lakshmi Prasad A. Drug–Excipient Interactions. [Presentation] Vadodara. 7th February 
2008. 
16. The American Association of Medical Chronobiology and Chronotherapeutics. 
Chronobiology and Chronotherapy of Arthritic Diseases [Online].2001 Available      
from: http://www.aamcc.net/cap2.htm [Accessed 20th October 2011] 
17. Lemmel EM, Leeb B, De Bast J, Aslanidis S. Patient and physician satisfaction with        
Aceclofenac: Results of the European Observational Cohort Study. Current Medical 
Research and Opinion 2002;18(3):146-153. 
18. Harrison. Principles of Internal Medicine. 16th ed. McGraw-Hill medical publishing 
division; 2005. p. 2037. 
19. Aceclofenac: A Potent Non-Steroidal Anti-Inflammatory Drug. [Online] Available from:  
http://www.pharmainfo.net/reviews/aceclofenac-potent-non-steroidal-anti-inflammatory-
drug [Accessed 26th October 2011]  
20. Jay L Goldstein, Leanne R Larson, Beverly D Yamashita. Prevention of Nonsteroidal 
Anti-inflammatory Drug-induced Gastropathy: Clinical and Economic Implications of  a 
Single-Tablet Formulation of Diclofenac/Misoprostol. American Journal of Managed 
Care 1998;4:687-697. 
21. Anil Pareek, Nitin Chandurkar, Anil Gupta, Ashish Sirsikar, Bhavik Dala, Bhavesh 
Jesalpura et al. Efficacy and Safety of Aceclofenac-CR and Aceclofenac in the treatment 
of Knee Osteoarthritis: A 6-Week, Comparative, Randomized, Multicentric, Double-Blind 
Study. The Journal of Pain 2011;12(5):546-553. 
22. Ballinger AB, Kumar PJ, Scott DL. Misoprostol in the prevention of gastroduodenal 
damage in rheumatology. Annals of the Rheumatic Diseases 1992;51:1089-1093. 
23. Davey PJ, Meyer E. The cost effectiveness of misoprostol prophylaxis a longside long-
term Nonsteroidal Anti-Inflammatory drugs. Implications of the MUCOSA trial. 
Pharmacoeconomics 2000;17(3):295-304. 
References 13 
 
99 Department of Pharmaceutics, Madras Medical College 
 
24.  Dooley M, Spencer CM, Dunn CJ. Aceclofenac: A reappraisal of its use in the 
management of pain and rheumatic disease. Drugs 2001;61(9):1351-1378. 
25. Fred E Silverstein, David Y Graham, John R Senior, Helen Wyn Davies, Barbara J 
Struthers,  Richard M Bittman. Annals of Internal Medicine 1995;123(4). 
26. George V. Papatheodoridis, Despina Papadelli, Evangelos Cholongitas, Dimitrios 
Vassilopoulos, Andreas Mentis, Stephanos J. Hadziyannis et al. Effect of Helicobacter 
pylori Infection on the Risk of Upper Gastrointestinal Bleeding in Users of Nonsteroidal 
Anti-inflammatory Drugs. American Journal of Medicine 2004;116:601– 605. 
27. Gerard Thiefina, MarieSophie Schwalm. Underutilization of gastroprotective drugs in 
patients receiving Nonsteroidal Anti-Inflammatory drugs. Digestive and Liver Disease   
2011;4:209–214. 
28. Li J, Liang X, Wang Q, Breyer RM, McCullough L, Andreasson K. Misoprostol, an anti-
ulcer agent and PGE2 receptor agonist, protects against cerebral ischemia. Neuroscience 
Letters 2008;438(2):210-215. 
29. Plosker GL, Lamb HM. Diclofenac/misoprostol. Pharmacoeconomic implications of 
therapy. Pharmacoeconomics 1999;16(1):85-98. 
30. Afsar C. Shaikh, Sayyed Nazim, Shaikh Siraj, Tarique Khan, M. Siddik Patel, Mohammad 
Zameeruddin et al. Formulation and evaluation of sustained release tablets of aceclofenac 
using hydrophilic matrix system. International Journal of Pharmacy and Pharmaceutical 
Sciences 2011;3(2):145-148. 
31. Ahmed A Bosela, Gamal M E Maghraby, Gamal M Mahrous. Design of Programmable 
Release Formulations for Combined Therapy. Indo-Global Journal of Pharmaceutical 
Sciences 2011;1(2):173-185. 
32. Basak S C. Controlled release HPMC matrix tablets of Propranolol hydrochloride. Indian 
Journal of Pharmaceutical Sciences. 2004;66(6):827-830. 
33. Bin Li, JiaBi Zhu, ChunLi Zheng, Wen Gong. A novel system for three-pulse drug release 
based on “tablets in capsule” device. International Journal of Pharmaceutics. 2008;352: 
159–164 
34. David Chen, Rong-Jer Tsay, Hue-In Lin, Huilan Chen, Shou-Chung Chao, Hao Ku. 
Stabilization and sustained-release effect of Misoprostol with Methacrylate copolymer. 
International Journal of Pharmaceutics 2000;203:141–148. 
References 13 
 
100 Department of Pharmaceutics, Madras Medical College 
 
35. James L Ford, Michael H Rubinstein, John E Hogan. Formulation of sustained release 
promethazine hydrochloride tablets using Hydroxypropylmethylcellulose matrices. 
International Journal of Pharmaceutics 1985;24:327-338. 
36. Jigar Mehta, Kanhaiyalal Patidar, Vipul Patel, Nayan Kshatri, Niranjan Vyas. Analytical 
Methods 2010;2(1):72-75. 
37. Karali TT, Catalano T. Stabilization of misoprostol with hydroxypropyl methyl cellulose 
against degradation of water. Pharmaceutical Research 1990;7(11):1186-1189. 
38. Oth M, Franz M, Timmermans J, Moes A. The bilayer floating capsule: a stomach-
directed drug delivery system for Misoprostol. Pharmaceutical Research 1992;9(3):298-
302. 
39. Indiran Pather S, Irina Russell, James A Syce, Steven H Neau. Sustained release 
theophylline tablets by direct compression Part 1: Formulation and in vitro testing. 
International Journal of Pharmaceutics 1998;164:1–10. 
40. Patil Dinesh, Sajeeth CI, Sirwani Rajesh, Santhi K. Modulation of Combined Release 
Behaviours from a Novel Pellets and Mini Tablet in Capsule System. International 
Journal of Research in Pharmaceutical and Biomedical Sciences. 2011;2(2).  
41. Raghavendra Rao NG, Gandhi Sagar, Patel Tarun. Formulation and Evaluation of 
Sustained release matrix tablets of Tramadol hydrochloride. International Journal of 
Pharmacy and Pharmaceutical Sciences 2009;1(1):60-70. 
42. Punna Rao Ravi, Sindhura Ganga, Ranendra Narayan Saha. Design and study of 
lamivudine oral controlled release tablets. American Association of Pharmaceutical 
Scientists PharmSciTech 2007;8(4):167-175. 
43. Raghavendra Rao NG, Mohd Abdul Hadi, Mansoori Wahid, M. R. Munde, Shrishail M. 
Ghurghure. Development and evaluation of tablets-filled-capsule system for 
Chronotherapeutic delivery of montelukast sodium. International Journal of Pharmacy 
and Technology 2011;3(1):1702-1721. 
44. Shinichiro Tajiri , Taro Kanamaru, Kamada Makoto, Tsutomu Konno, Hiroaki Nakagami. 
Dosage form design and in vitro/in vivo Evaluation of Cevimeline Extended-release tablet 
formulations. International Journal of Pharmaceutics 2010;383:99–105. 
References 13 
 
101 Department of Pharmaceutics, Madras Medical College 
 
45. Santanu Ghosh, Barik BB. Preparation and evaluation of Aceclofenac sustained release 
formulation and comparison of formulated and marketed product. International Journal of 
Medicine and Medical Sciences. 2009;1(9):375-382. 
46. Syed Azeem Hyder, Syed Ali ul hasan, Shaweta Sharma. Formulation & Optimization Of 
Immediate Release Tablet Of Rupatadine Fumarate. International Journal Of Pharma 
Professional’s Research 2011;2(3):345-350. 
47. Sharma Shailesh, Singh Gurjeet, Gupta GD. Formulation design and optimization of 
Mouth dissolving tablets of domperidone using sublimation technique. Pharma science 
monitor 2010;1(1):128-136. 
48. Shivakumar HN, Sarasija Suresh, Desai BG. Design and evaluation of ph sensitive 
minitablets for chronotherapeutic delivery of theophylline. Indian journal of 
Pharmaceutical sciences 2007;69(1):73-79. 
49. Umesh D, Shivhare, Nandkishor D Adhao, Kishore P Bhusari, Vijay B Mathur, Digvijay 
U Ambulkar. Formulation development, evaluation and validation of Sustained release 
tablets of Aceclofenac. International Journal of Pharmacy and Pharmaceutical Sciences 
2009;1(2). 
50. Ian J Hardy, Anne Windberg-Baarup, Claudia Neri, Paul V Byway, Steven W Booth, 
Shaun Fitzpatrick. Modulation of drug release kinetics from hydroxypropyl methyl 
cellulose matrix tablets using polyvinyl pyrrolidone. International Journal of 
Pharmaceutics 2007;337:246–253. 
51. Harris Shoaib M, Jaweria Tazeen, Hamid A Merchant, Rabia Ismail Yousuf. Evaluation of 
drug release kinetics from Ibuprofen matrix tablets using HPMC. Pakistan Journal of 
Pharmaceutical Sciences 2006;19(2):119-124. 
52. Khanvilkar KH, Huang Y, Moore AD. Influence of Hydroxypropyl methylcellulose 
mixture, apparent viscosity, and tablet hardness on drug release using a 2(3) full factorial 
design. Drug Development and Industrial Pharmacy 2002;28(5):601-608. 
53. Melanie Dumarey, Hakan Wikstrom, Magnus Fransson, Anders Sparen, Pirjo Tajarobi, 
Mats Josefson et al. Combining experimental design and orthogonal projections to latent 
structures to study the influence of microcrystalline cellulose properties on roll 
compaction. International Journal of Pharmaceutics 2011;416:110– 119. 
References 13 
 
102 Department of Pharmaceutics, Madras Medical College 
 
54. Mira Jivraj, Luigi G Martini, Carol M Thomson. An overview of the different excipients 
useful for the direct compression of tablets. PSTT 2000;3(2):58-63. 
55. Obae K, Iijima H, Imada K. Morphological effect of Microcrystalline cellulose particles 
on tablet tensile strength. International Journal of Pharmaceutics 1999;182:155–164. 
56. Ranjani V Nellore, Gurvinder Singh Rekhi, Ajaz S Hussain, Lloyd G Tillmand,  Larry L 
Augsburger. Development of Metoprolol tartrate extended-release matrix tablet 
formulations for regulatory policy consideration. Journal of Controlled Release 1998;50: 
247–256. 
57. Takumi Magome, Kazuhiro Obae, Yoshihito Yaginuma. Tableting properties of novel 
microcrystalline cellulose Ceolus KG-1000 Vs other microcrystalline cellulose products in 
roller compaction. 2007 AAPS Annual Meeting & Exposition 2007;9- 13. 
58. Sean C Sweetman. Martindale-The Complete Drug Reference. 36th ed.                    
London: Pharmaceutical Press.2009;2:2407 
59. Joint Formulary Committee. British national formulary. BNF 57. London: BMJ publishing 
group & RPS publishers;2009. p. 554 
60. Aceclofenac [Online]. Available from: http://www.mims.com/India/drug/search/ 
aceclofenac [Accessed 20th November 2011]. 
61. Misoprostol [Online]. Available from: http://www.mims.com/USA/drug/search/ 
Misoprostol [Accessed 20th November 2011]. 
62. Misoprostol [Online] Available from: http://www.ipas.org/Library/Other/ 
Registered_Misoprostol_Drugs_2007_by_country [Accessed 25th November 2011]. 
63. Misoprostol  [Online] Available from : http://drugbank.ca/drugs/DB00929 [Accessed  20th 
November 2011] 
64. Cytotec  [Online] Available from : http://www.rxlist.com/cytotec-drug.htm [Accessed  
20th November 2011] 
65. Cytotec [Online] Available from : http://www.accessdata.fda.gov/drugsatfda_docs 
/label/2009/019268s041lbl.pdf [Accessed 20th November 2011] 
66. The Department of Health. British Pharmacopoeia. London: Stationary Office;2009. Vol. 
I-II p.78, 3999. 
67. Clarke. Analysis of drugs and poison. 2nd ed. London: Pharmaceutical press; 2004. 
References 13 
 
103 Department of Pharmaceutics, Madras Medical College 
 
68. Goodman and Gilman. Manual of Pharmacology and Therapeutics. 11th ed. New York: 
McGraw-Hill: Medical Publication division; 2008 p. 626. 
69. Tripathi KD. Essentials of Medical pharmacology. 5th ed. New Delhi:Jaypee Brothers; 
2003. p.594. 
70. Ministry of Health and Family Welfare. Indian Pharmacopoeia. New Delhi: The 
controller of publications,2010;Vol.I-III. p. 192-193,751-754,770, 1699. 
71. Ceolus [Online]. Available from: www.ceolus.com/ceolus [Accessed 20th Jul 2011]. 
72. Raymond C Rowe, Paul J Shesky, Marian E Quinn. Handbook of Pharmaceutical 
Excipents. 6th ed. London: Pharmaceutical Press and American Pharmacists Association; 
2009. 
73. Kazuhiro Obae. Improving of compactability and friability in high dose tablets using 
novel microcrystalline cellulose CeolusTM KG-1000 [Presentation] 16th Apr 2008. 
74. Robbins and Cotran. Pathologic basis of disease. 7th ed. Pennsylvania: Elsevier Inc;2005.  
75. Timothy Beukelman, Nivedita M Patkar, Kenneth G Saag, Sue Tolleson- Rinehart, Randy 
Q Cron, Morgan DEwitt ESI, et al. American college of Rheumatology. Education 
treatment and research. Arthritis Care and Research 2011;63(4):465-482. 
76. National Institute for Health and Clinical Excellence [Online] Osteoarthritis: The care and 
management of osteoarthritis in adults. Available at www.nice.org.uk/CG059. [Accessed  
20th  November 2011] 
77. Assil Saleh. Rheumatoid arthritis: Disease pathogenesis. Advanced Studies in Nursing 
2008;6(2):26-31. 
78. Hitesh P Patel, Preeti Karwa, Rama Bukka, Nitesh J Patel. Formulation and evaluation of 
Immediate release tablets of Zolpidem tartrate by direct compression. International 
Journal of Pharmaceutical Sciences Review and Research 2011;7(2):80-85  
79. United States Pharmacopoeia 30 and National Formulary 25. Rockville Maryland: Unites 
States Pharmacopoeial Convention, 2009.  
